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ABSTRACT

The overall goal of this project is to characterize the teratogenic potential of 4-OMethylhonokiol (MH) and to identify the underlying mechanisms of teratogenesis. Although
Magnolia extracts have been reported previously for their cardioprotective effects, including antiobesity, anti-atherosclerosis, and vascular relaxation, toxicity data are lacking. Effects of Magnolia
compounds on embryonic development are not known yet. Therefore, the potential toxic effects
of MH, a major bioactive constituent of Magnolia grandiflora seeds or Magnolia officinalis bark on
Japanese medaka embryogenesis and on locomotion during larval stage were studied.
MH exposure caused a slow heartbeat, blood occlusion, absence of blood circulation,
decreased hatching efficiency, and increased mortality in medaka embryos in a concentrationand time-dependent manner. MH might cause blood vessel occlusion by increasing the
expression of FVII, FX, FXI of the blood coagulation pathway and decreasing the fold differences
between the tissue plasminogen activator (tPA) and the plasminogen activator inhibitor-1 (PAI-1)
of the thrombolytic system. MH might also damage the blood vessels through production of
excessive pro-inflammatory mediators or reactive oxygen species, which resulted in blood vessel
occlusion. Another objective of this study was to evaluate the effect of MH on locomotion in 2
days post hatch (dph) larvae. Exposed larvae showed an overall decline in the duration of
movement after the first dark cycle relative to the untreated controls, however the change was
not significant.
An additional goal of this project was to characterize the Wnt/β-catenin signaling pathway
to unravel the adverse potential of MH on the cardiovascular system (CVS). Our study suggested
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that MH-mediated cardiovascular injury may be caused due to upregulation of some major
components of the Wnt/β-catenin pathway through expression of excessive pro-inflammatory
mediators. Moreover, MH decreased expression of ErbB3 and NRG-2 suggesting impaired
cardiac structure.
This project established the concentration-and time-dependent teratogenic potential of
MH on the cardiovascular system during medaka embryogenesis. Moreover, it revealed potential
mechanisms for producing these toxicities.
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CHAPTER 1: INTRODUCTION
1.1 Background of natural products
The impact of natural products on human health has been tremendous. There are diverse
sources of natural products including plants, animals and microorganisms. Paleoanthropological
evidence shows that Neanderthals might have known about the medicinal properties of plants
more than 60,000 years ago, which was evidenced by pollen deposits found near the Zagros
Mountains of Kurdistan in Iraq (Solecki, 1975). Natural products have been used as therapeutic
agents in traditional Chinese medicine for years. The ancient Chinese medicinal books “Wu Shi
Er Bing Fang” (Prescriptions for Fifty-Two Diseases), compiled around 350 BC, documented 247
natural agents and about 150 combinatorial drug formulae along with the efficacies, properties,
and synergies of natural products (Ji et al., 2009; Jiao and Wang, 2005; Wan and Zhong, 1990).
During the Eastern Han dynasty (25-220 AD), a monograph named “Shen Nong Ben Cao Jing”
(Shen Nong Materia Medica) listed 252 medicinal plants and 67 medicinal animals (Gao, 2004).
China published the first national Pharmacopaeia titled “Xin Xiu Ben Cao” (Newly Revised
Medicinal Materials), which documented 850 agents during 659 AD (Gao, 2004). Li Shi-Zhen, a
Chinese scientist, pharmacologist, and herbalist issued his work “Ben Cao Gang Mu”
(Compendium of Medicinal Materials) in 1587 AD that listed 1,892 agents and about 11,000
combinatorial formulae (Gao, 2004). The introduction of structural and analytical chemistry has
helped with the purification and structural elucidation of diverse compounds and is used as an
important tool to know their mechanisms in the physiological system. In 1805, morphine was
isolated from opium by Friedrich Wilhelm Serturner and became not only the first naturally derived
medicine but also the first one to be commercialized by Merck in 1826 (Ji et al., 2009).
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Although almost all civilizations show evidence of uses of natural products, they have not
received popularity until the Nobel Prize winning isolation of penicillin by Sir Alexander Fleming
in 1945 (Ji et al., 2009; Shen, 2015). Around 50% of all drugs approved between 1981-2014 came
directly or indirectly from natural products (Table 1.1).
Table 1.1: All new drugs approved from 1981 to 2014
Sources of drugs

Number of drugs approved (%)

Unaltered natural product

67 (4%)

Natural product derivative

320 (21%)

Mimic of natural product (/NM)

172 (11%)

Botanical drug

9 (1%)

Biological macromolecule

250 (16%)

Synthetic drug

420 (27%)

Synthetic drug-NP Pharmacophore (S*)

61 (4%)

Vaccine

101 (6%)

S*/NM

162 (10%)

S*- Synthetic drug-NP Pharmacophore; /NM- Mimic of natural product (Newman and Cragg,
2016)
Unfortunately, companies reduced investments in natural product discovery because of
progress towards combinatorial synthesis and high throughput screening in the early 1990s (Ji et
al., 2009). However, because of the inadequacy of newly discovered drug entities, scientists
decided to turn their attention back to natural product discovery. Moreover, the Nobel Prize
winning work in 2015 for the discovery of a plant natural product, artemisinin, by Dr. Youyou Tu
to eliminate malaria and the discovery of a microbial natural product, avermectin, by Dr. Satoshi
Omura and William C. Campbell to treat lymphatic filariasis and onchocerciasis have encouraged
companies to invest more in the discovery of natural products (Shen, 2015).
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1.2 Magnolia constituents and their therapeutic effects
The Magnolia genus was named in 1703 by Charles Plumier after a French botanist, Pierre
Magnol (Plumier, 1703). Magnolia bark has been used in traditional Chinese and Japanese
medicine for years to treat diverse diseases, including asthma, allergic diseases, fever,
gastrointestinal disorders, headaches, muscular pain, and neurological disorders such as,
anxiety, and depression (Amdlard et al., 2007; Dharmananda, 2002; Lee et al., 2011; Li et al.,
2007; Liu et al., 2007; Poivre and Duez, 2017). The Magnolia genus has at least 255 different
ingredients including alkaloids, coumarins, flavonoids, lignans, neolignans, phenylpropanoids and
terpinoids (Ito et al., 1982; Tachikawa et al., 2000; Lee et al., 2011). Among these, several
neolignan ingredients, including 4-O-Methylhonokiol (MH), honokiol, magnolol, and obovatol (Fig.
1.1) have been receiving great attention because of their wide range of therapeutic potentials
against various diseases. In a previous study, honokiol was able to show anti-proliferative activity
by inhibiting VEGFR2/Flk/KDR auto phosphorylation in human endothelial cells at a concentration
of 37.6 µM (Bai et al., 2003). Moreover, it was able to inhibit VEGF-induced Rac activation (Zeng
et al., 2001). Rac is known to promote VEGF-induced endothelial migration and proliferation
(Colavitti et al., 2002; Zeng et al., 2002). Magnolia constituents have shown anti-platelet activity
(Lee et al., 2011). Magnolol were proven to inhibit collagen (IC50 =504 µM) and arachidonic acid
(AA) (IC50=36 µM) induced aggregation of platelet rich plasma in rabbits (Teng et al., 1990).
Honokiol is more potent in inhibiting collagen (IC50=90 µM) and AA (IC50=3 µM) -induced platelet
aggregation (Teng et al., 1990).
Both of honokiol and magnolol show anti-platelet activity by inhibiting thromboxanes (TXA)
formation, an agonist of platelet activation and contributor of thrombus formation (Lee et al.,
2011). Moreover, the compounds inhibit intracellular calcium mobilization, an event necessary for
platelet activation and aggregation (Lee et al., 2011). Honokiol was proven to be 5-10 times more
potent than magnolol to inhibit AA induced platelet aggregation in rats (Pyo et al., 2002). Another
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major component of the Magnolia family, obovatol, also inhibits epinephrine and AA induced
platelet aggregation (Pyo et al., 2002).

OH
OH
O
Obovatol

Figure 1.1: Structures of bioactive constituents of Magnolia genus

Anti-oxidant activity of both honokiol and magnolol can be exploited to treat
atherosclerosis. Honokiol (2.5-20 µM) prevents oxidized LDL-mediated dysfunction by decreasing
oxidized LDL-mediated adhesion molecule and improving expression of oxidized LDL-diminished
NOS protein in endothelial cells (Ou et al., 2006). Magnolol inhibits proliferation of cardiac
fibroblast by blocking ROS generation, thus exerting protective effect on the vascular system
(Chen et al., 2006; Liou et al., 2009). Moreover, honokiol and magnolol cause p21-mediated cell
cycle arrest and inhibit VSMC proliferation, which offers the possibility to treat atherosclerosis
(Lee et al., 2006; Lin et al., 2009). MH reduces high fat diet (HFD) induced plasma triglycerides,
cholesterol level, and prevents insulin resistance (Zhang et al., 2015). Moreover, it lowers alanine
transaminase (ALT) activity, hepatic triglyceride level, liver weight, and improves hepatic steatosis
(Zhang et al., 2015).
4

The Magnolia neolignans exert cytotoxic effects used as therapeutic agents in cancer. The
Magnolia constituents can show this effect by targeting many pathological relevant pathways
(Arora et al., 2012; Poivre and Duez, 2017). Honokiol and its analogs were reported to inhibit NFkB by suppressing protein kinase B (AKT), preventing IKK activation, IkBα activation and NF-kB
nuclear translocation (Poivre and Duez, 2017). MH was able to induce apoptosis in SiHa human
cervical cancer cells by increasing peroxisome proliferator-activated receptor-gamma (PPARγ)
activation and inhibiting PI3K/Akt pathway and intrinsic pathway induction (Hyun et al., 2015).
Studies also show that neolignans are able to down regulate EGFR signaling and
phosphorylation, thus inhibiting several human cancer cell lines (Fried and Arbiser, 2009; Arora
et al., 2012; Kaushik et al., 2012). Neolignans, especially honokiol, can induce apoptosis by
activating mTOR and its downstream signaling pathway and by inhibiting AKT and extracellular
signal regulated kinases (ERK) signaling pathways (Liu et al., 2007; Fried and Arbiser, 2009; Lee
et al., 2011; Arora et al., 2012; Kaushik et al., 2012; Poivre and Duez, 2017). MH decreased
phosphorylation of Rb and anti-apoptotic proteins and increased the expression of cell cycle
regulator p21 and apoptotic proteins at a concentration of 20 µM in prostate cancer cell lines (Lee
et al., 2013). In addition, the compound inhibited NF-kB activity and enhanced PPARꝩ activity,
which altogether showed therapeutic potential against prostate cancer (Lee et al., 2013).
Honokiol, magnolol and obovatol show anti-inflammatory activity by inhibiting NF-kβ
pathway, important regulator of inflammation. MH (2.5-10 µM) also has anti-inflammatory effects
through inhibition of LPS (1 µg/ml) induced NO generation by inhibition of NF-kB pathway in
macrophage RAW 264.7 cells (Zhou et al., 2008; Oh et al., 2009). MH is also able to inhibit TPAinduced inflammatory ear edema in mice through inhibition of NF-kB, iNOS and COX-2 production
(Zhou et al., 2008; Oh et al., 2009). Moreover, previous studies show that honokiol and magnolol
exert anti-oxidative and anti-inflammatory activity through downregulating IFN-γ induced pERK1/2 and its downstream pathway for ROS and NO production (Chuang et al., 2013).
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Components of Magnolia also show therapeutic potential against neuronal diseases. They
show an anxiolytic effect mediated through GABA receptor/Cl- channel activation (Lee et al.,
2011). Magnolia components such as magnolol and honokiol may be involved with an antidepressant effect by normalizing biochemical abnormalities of serotonin and its metabolite, serum
corticosterone level and platelet adenylate cyclase activity (Lee et al., 2011). Several components
of Magnolia, including honokiol and MH proved to have neurotrophic potential against Alzheimer’s
disease and nerve injuries through mitogen activated ERK kinase (MEK) (Lee et al., 2011). MH
(1 µM) was found to enhance neurite outgrowth and induction of neurotrophic factors via ERK
activation (Lee et al., 2009).
1.3 Toxicological effects of Magnolia family
Magnolia extracts have been used in traditional Chinese medicines without clear
manifestations of safety concerns (Poivre, and Duez 2017). Few studies have been performed to
evaluate the toxic potential of Magnolia bark extract. One study was designed to observe if the
ethanol extract (94% magnolol and 1.5% honokiol) of Magnolia bark showed any mutagenic effect
in Salmonella typhimurium or Escherichia coli. Under their experimental conditions, Magnolia bark
extract did not show any mutagenic effect in S. typhimurium and E. coli (Li et al., 2007a, b, c). In
another in vitro study, Magnolia bark extract did not show genotoxicity in Chinese hamster ovary
(CHO) cells and Chinese hamster lung tissue (V79) cells (Zhang et al., 2008). In an in vivo study
with male and female Swiss albino (CD-1) mice of 7-9 weeks old, oral administration (625-2500
mg/kg) of ethanol extract (94% magnolol and 1.5% honokiol) of Magnolia bark did not have any
effect on the ratio of immature to total erythrocytes (Li et al., 2007a, b, c). Moreover, the number
of micronucleated polychromatic erythrocytes did not increase significantly in the Magnolia bark
extract-treated group compared to the negative control group (Li et al., 2007a, b, c; Lee et al.,
2011). Previous findings did not show any effects on microscopic and macroscopic or clinical
observation, urine or clinical chemistry, hematology or organ weight measurements with the
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Magnolia treated group (Lee et al., 2011). Most importantly neither mortality nor significant
changes in body weight were observed with the Magnolia bark extract-treated group (Liu et al.,
2007). All the above findings suggest that Magnolia bark extracts have very few adverse effects
and low toxicity. However, it is important to characterize the adverse effects and toxic potential of
these extracts in various species at different concentrations and through various routes of
administration (Lee et al., 2011).
1.4 Overview of the blood coagulation pathway
The concept of blood coagulation was introduced in 1960 when a group of scientists
including Davie, Ratnoff, and Macfarlane first mentioned the “Cascade” and “Waterfall” theories,
delineating the fundamental principle of a cascade of proenzymes that was activated through
proteolytic cleavage leading to activation of downstream enzymes (Achneck et al., 2010; Palta et
al., 2014). The coagulation cascade is divided into three pathways- the intrinsic, extrinsic, and
common pathways (Fig. 1.2).
Extrinsic pathway: The extrinsic pathway is activated by tissue factor (TF) that results from
damage in the endothelium and exposure in the subendothelial matrix (Lasne et al., 2006). The
endothelium minimizes the interaction between the TF, and plasma procoagulants under normal
physiological conditions but exposes TF to interact with the plasma protease factor (F) VII a and
calcium, forming a proteolytic complex composed of lipoproteins and phospholipids that will
enzymatically activate FX to FXa (Owens and Mackman, 2010; Bom and Bertina, 1990).
Intrinsic Pathway: The intrinsic pathway is a parallel pathway for blood coagulation,
activated in response to vascular injury when FXII (Hageman factor) interacts with the exposed
subendothelial substances. When the blood vessels are damaged, a series of proteolytic events
collectively known as contact activation reactions are initiated, including the activation of FXII,
prekallikrein (PK), and FXI and cleavage of high molecular weight kininogen (HK) (Kaplan and
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Silberberg, 1987; Cochrane and Griffin, 1982; Kaplan et al., 1997; Colman and Schmaier, 1997).
The intrinsic pathway is initiated through activation of FXI by activated FXII (FXII a). FXI further
activates FIX, which then forms a tenase complex with its co-factor (FVIII) on a phospholipid
surface (Hall, 2010; Kumar et al., 2010; Palta et al., 2014). The resultant tenase complex will then
activate FX.
Common Pathway: Both the extrinsic and intrinsic pathways coincide at the common
pathway. Activated factor X (FXa) forms a prothrombinase complex along with its co-factor (FVa)
that is attached to the surface of platelets, platelets phospholipids, tissue phospholipids, and
calcium ions (Ca2+), which catalyzes the conversion of prothrombin to thrombin (Roncales, 2000).
Thrombin plays important role in the clot formation by two different mechanisms. Thrombin
promotes proteolytic cleavage of fibrinogen to fibrin monomer that polymerizes to form fibrin
fibers, and ultimately leads to the formation of the long fibers of clot reticulum (Alcott et al., 2009).
Moreover, thrombin activates factor XIII (XIIIa), which creates covalent bonds between the fibrin
fibers. This forms a fibrin network that strengthens the clot and produces a secondary hemostatic
plug (Hall, 2010; Kumar et al., 2010).
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Figure 1.2: The blood coagulation pathway. The coagulation pathways are activated by a
cascade of reactions in which a stable form of the protein is converted into an enzyme that will
catalyze the next reaction. The intrinsic pathway is comprised of factor XII, XI, IX, and VIII. Factor
VII is a unique factor of the extrinsic pathway, which is initiated by exposure of blood to tissue
factor (Tavares-Dias and Oliveira, 2009). The final common pathway is activated either or both
by extrinsic or intrinsic pathway that results in the conversion to thrombin. During injury to the
vessels, thrombin is produced from prothrombin in the presence of factor Xa with cofactor Va.
Thrombin plays important role in the conversion of fibrinogen to fibrin (Pallister and Watson,
2010).
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1.4.1 Overview of the blood coagulation pathway in the teleost
Fish have delicate gills where oxygenation occurs, and the oxygenated blood is distributed
throughout the body. In case of any damage in the gills, the fish will bleed to death unless it has
any compensatory mechanism to control blood loss. Fish thrombocytes are biological cells
equivalent to the platelets in mammals and play a role in homeostasis (Tavares-Dias and Oliveira,
2009). The presence of thrombocytes in fish was first reported in 1924 by Jordan and Speidel
(Jordan and Speidel, 1924). In the teleost, thrombocytes are produced by the kidney and spleen.
They first appear in the spleen during the first week of post fertilization and appear in the blood
after the fourth week of fertilization (Romano et al., 1997). The half-life of thrombocytes in the
circulation is up to four days, however some can survive up to 70 days (Tavares-Dias and Oliveira,
2009). The short half-life indicates the necessity of frequent substitution of these cells in order to
maintain homeostasis (Fischer et al., 1998). It has been confirmed that the coagulation
mechanisms in teleosts and mammals are similar in spite of their significant distance in evolution
(Doolittle et al., 1962; Doolittle 1965; Cottrell and Doolittle, 1976; Doolittle et al., 1976; Doolittle
and Feng, 1987; Doolittle, 1993; Wang et al., 1989). The intrinsic, extrinsic and common
coagulation pathways are also present in the teleost, however, the major coagulation event is the
conversion of the catalyzed thrombin to fibrinogen in blood plasma and the production of fibrin
clot (Tavares-Dias and Oliveira, 2009).
Tissue factor-based coagulation in fish was first reported in 1962 (Doolittle and Surgenor,
1962; Doolittle, et al., 1962). Prothrombin, thrombin, fibrinogen, plasminogen and higher
concentration of calcium are also present in teleost (Doolittle et al., 1962; Doolittle 1965; Cottrell
and Doolittle, 1976; Doolittle et al., 1976; Doolittle and Feng, 1987; Wang et al., 1989). The clotting
time was over one minute when the calcium concentration was 20-30 mmol/l, which was the
fastest time compared to the other species (Doolittle and Surgenor, 1962). The blood coagulation
time in fish is faster than mammals (Wolf, 1959; Doolittle and Surgenor, 1962; Smit and
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Schoonbee, 1988), because it contains larger number of coagulation factors, which leads to the
higher activity of extrinsic and intrinsic pathway in fish (Doolittle and Surgenor, 1962; Smit and
Schoonbee, 1988). Fish thrombocytes, essential sources of phospholipids, lead to the activation
of coagulation factors that convert prothrombin into thrombin, which catalyze the activation of
fibrinogen, thus triggering thrombocyte aggregation (Tavares-Dias and Oliveira, 2009). Therefore,
the number of thrombocytes plays an important role in this process, and faster clotting time
indicates an increased number of thrombocytes in fish (Casilas and Smith, 1977; Ranzani-Paiva
et al., 2000).
1.4.2 Teleost does not have any Plasma Kallikrein-Kinin system
The kallikrein-kinin system (KKS) has been involved in cardiovascular regulation,
inflammation, immune function, pain perception, and kidney function in vertebrates (Golias et al.,
2007; Petho and Reeh, 2012; Wong and Takei, 2013). KKS consists of FXII, the complex of
prekallikrein (PK) and high molecular weight kininogen (HK) (Bryant and Shariat-Madar, 2009).
FXIIa converts plasma to kallikrein, which, along with other stimuli, generates bradykinin (BK) and
activates HK (HKa). Elevated BK is an indication of the pathogenesis of coagulopathy,
endotoxemia, hypertension, and inflammation that has been implicated with KKS (Bryant and
Shariat-Madar, 2009). In mammals, plasma KKS and tissue KKS are the two major cascades for
kinin formation (Lalmanach et al., 2010). HK is cleaved to nonapeptide BK by plasma kallikrein
(KLKB1) in the plasma KKS (Fig. 1.3). Low molecular weight kininogen (LK) is cleaved to
decapeptide [Lys0]-BK or kallidin by tissue kallikreins (KLKs) in the tissue KKS (Fig. 1.3) (Wong
and Takei, 2013).
The contact activation system for Hageman factors (FXII) in thrombi formation and plasma
kallikrein are not present in the teleosts (Doolittle, 2011). Moreover, the enzyme that is
responsible for forming BK is also unknown (Doolittle, 2011). HK and LK are products of
alternative splicing from the same gene, kininogen (KNG), in humans, and HK has two extra
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domains than LK, such as D5 and D6 (Lalmanach et al., 2010). During contact activation in blood
coagulation, positively charged D5 interacts with the negatively charged surface of the
endothelium, and D6 interacts with the apple domain of KLKB1 that increases the binding affinity
between HK and KLKB1 (Pathak et al., 2013). The KNG genes in fish do not have the D5 and D6
regions at genomic levels and D5 and D6 transcript regions in the nucleotide and expressed
sequence tags (EST) databases of teleosts were also not found (Zhou et al., 2008), which
confirms that the alternative splicing mechanisms of KNG1 are absent in the teleosts (Wong and
Takei, 2013). In teleosts, the precursor protein, HK, the enzyme that cleaves the HK into BK,
KLKB1, and the active peptide, BK, all were absent (Fig. 1.3); however, it is not known whether
these genes were deleted or never evolved in those species because in the conserved synteny
regions no pseudogene of KLK1 was observed (Wong and Takei, 2013). A novel immunoassay
technique showing the presence of [Argo]-BK as the major circulating kinin, along with the
identification of the KLK-like group in the genome of teleosts, confirm the presence of [Arg o]-BK
as the single effector of the KKS in teleosts (Fig. 1.3). [Argo]-BK is proven to be more potent than
BK in triggering anti-dipsogenic and cardiovascular effects in eel, which suggest that [Arg o]-BK
has more affinity towards the endogenous BK receptors than BK (Takei et al., 2001). The retention
of a single KKS in teleosts from the common ancestor play a significant role to study the original
function of KKS in terms of evolutionary perspective.
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Figure 1.3: The teleost lack the Plasma Kallikrein-Kinin system (KKS). The plasma KKS
system of the mammals consists of KNG, HK, KLKB1, and BK; tissue KKS system consists of
KNG, LK, KLKs and decapeptide, [Lys0]-BK. Teleosts do not have the cascade that is equivalent
to the plasma KKS in mammals. The HK and KLKB1 are absent in teleost and [Arg o]-BK is the
major circulating kinin instead of BK. [Argo]-BK can be produced from cleavage of Kininogen,
equivalent to mammals LK, by kallikrein-like enzymes. In teleosts, small amounts of BK can be
produced from cleavage of [Argo]-BK by aminopeptidase. AA-amino acids. (Wong and Takei,
2013)

1.4.3 Fibrinolytic system
The teleost showed essential features of the thrombolytic pathway, including the activators
(tissue-type plasminogen activator-t-PA; urokinase-type plasminogen activator-u-PA) and
inhibitor (Plasminogen activator inhibitor-1, PAI-1) of the pathway (Hanumanthaiah et al., 2002;
Lee et al., 2016; Ogiwara et al., 2015). The fibrinolytic system acts as a regulatory mechanism
against the blood clots. When the injured blood vessels are healed, thrombi are lysed by plasmin.
Fibrinolysis regulates the degradation of fibrin through interaction of diverse plasminogen
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activators (u-PA, and t-PA) and inhibitors (PAI-1, Thrombin activatable fibrinolysis inhibitor-TAFI).
Both the activators (uPA and tPA) have short half-lives (4-8 minutes) because of the presence of
high concentrations of inhibitors, such as PAI-1 (Chapin and Hajjar, 2015). uPA has a lower affinity
than tPA for plasminogen. Plasminogen is converted to plasmin, which is responsible for
proteolysis of fibrin results in soluble fibrin degradation products (Fig. 1.4). PAI-1 is released from
the endothelial cells, platelets and other cells into the circulation that inhibits tPA and uPA rapidly
(Coolman et al., 2006). Elevated expression of PAI can result in excessive amount of fibrin
deposition, and therefore tissue will be damaged by suppressing the fibrinolytic system.

Figure 1.4: Overview of the fibrinolytic system. PAI-1 Plasminogen Activator inhibitor, t-PA
tissue type plasmonigen activator, u-PA Urokinase plasminogen activator, TAFI Thrombin
activatable fibrinolysis inhibitor, α2-AP α2 Antiplasmin. (Meltzer, 2010; Kaliappan et al., 2011)
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1.5 Japanese medaka in toxicity testing
Applications of alternative species, especially small fish, are gaining popularity because
of the wide range of advantages they offer. Small fish are convenient vertebrate models in all
types of toxicity tests that can be used as an ecological sentinel, to identify mammalian toxicity
as well as mechanisms for toxicity (Law, 2001; Shima and Mitani, 2004; Hinton el al., 2005). Acute
or chronic exposure as well as multigenerational exposure of compounds can be administered
either on the embryos or the adult fish (Padilla et al., 2009). Moreover, the fish offers additional
advantages by providing sophisticated experimental tools such as transgenic lines (Fu et al.,
2000; Wayne et al., 2005) and morpholino knock down techniques (Carl et al., 2002; PaulPrasanth et al., 2006).
Japanese medaka is currently one of the widely used vertebrate fish models. As the name
suggests Japanese medaka is native to Asian countries, primarily Japan. It is a small (2-4 cm),
egg-laying fish that is hardy, and survives in wide latitudes of salinity and temperature (Padilla et
al., 2009), which makes them suitable to adapt to laboratory conditions. Medaka has several
advantages over mouse as an experimental model, including the production of a large number of
progeny by the same two parents, the availability of a large number of embryos because of daily
spawning, low cost and easy maintenance, transparent chorion, which allows high-throughput
screens for developmental abnormalities during embryogenesis, and a short generation time (2
months) (Hyodo-Taguchi and Egami, 1985; Hyodo-Taguchi and Egami, 1989). Medaka plays a
significant role in toxicology testing. The low cost and smaller size of medaka allow researchers
to use a small amount of toxicant, more numbers per dosage group, and large treatment groups.
Moreover, medaka is an excellent model for developmental toxicity because it can avoid maternal
metabolism, and can be observed daily under the microscope. It is a convenient model to
determine the acute and chronic toxicity and to unravel the mechanisms associated with toxicity.
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1.5.1 Major developmental stages of medaka embryos
Medaka embryos are divided into 39 developmental stages based on the diagnostic
features of the developing embryos (Iwamatsu, 2011). The stages related to our experiment will
be discussed in this section. The heart first appears between the posterior region of the mid-brain
and the anterior region of hind-brain in stage 22. In the next stage, the anterior portion of the heart
continues to straighten, grow and reaches the posterior end of the eye vesicle. The cuvierian
ducts (blood vessels), semicircular in shape, and the vitello-caudal vein begin to form on the yolk.
A blood island appears between the 6th and 11th somites in the ventral region. During stage 24,
the anterior portion of the heart extends to the anterior end of the forebrain and exhibits a slow
heartbeat (33-64/min) (Iwamatsu, 2004). The Cuvierian ducts and vitello-caudal vein are not
completed yet. The blood starts circulating in Stage 25, in which the spherical blood cells are
pushed out from the blood island (located in the 7th to 15th somites) toward the vitello-caudal vein
(Kinoshita et al 2009). The blood is pumped at a rate of 70-80/min from the heart into the anterior
cardinal vein and the dorsal aorta roots (Iwamatsu, 2004). However, a blood countercurrent is
observed into the aorta from the heart (Kinoshita et al 2009). Chamber differentiation of the heart
also begins in this stage. Anterior and posterior portions of the heart tube differentiate into the
atrium and ventricle, respectively. The differentiation of the heart cells into atrium, ventricle, sinus
venosus and bulbous arteriosus occur in stage 29 (3 days and 2 hours). The chamber
differentiation and correct positioning of the heart are completed by stage 36 (6 days). During
stage 39, the tip of the caudal fin extends towards the base of the pectoral fin or the posterior
region of the swim bladder (Kinoshita et al 2009). The internal wall of the swim bladder enlarges
after hatching, and the cells in the hatching gland disappear by this time. Finally, the embryos
dissolve the inner layer of egg envelope, tear the outer layer and escape from the tail of the
envelope first.
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1.5.2 Development of heart in Japanese medaka
The heart is the first functional organ formed in the vertebrate embryo. The embryonic
heart tube is a relatively simple organ consisting of myocardium and endocardium, which form
the outer and inner layer of the tube, respectively (Fishman and Chien, 1997). There are three
diverse cell types in the heart including myocardiocytes, muscular cells that provide cardiac
contractility; endocardiocytes, endothelial cells that provide continuity with the vascular
endothelium; and additional lineage diversification, which creates subpopulation such as
ventricular and atrial myocardiocytes and show distinct physiological and histological
characteristics (De-Haan, 1965; Franco et al., 1998; Lyons, 1994; Satin et al., 1988; Yelon, 2001).
Heart development occurs in the same manner both in Japanese medaka and zebrafish, however,
the development takes place over a longer time in medaka, which allows high-resolution detailed
observation of cardiac cell differentiation (Kinoshita et al., 2009). The transparent chorion of the
embryos provides great advantage by permitting high-throughput screens for developmental
abnormality.
Lemanski et al. (1975) reported the fine structure of the medaka heart that is located in
the anterior ventral region of the abdominal cavity, immediately posterior to the gills. The primitive
heart tube is composed of four chambers: (1) the sinus venosus, a thin-walled distensible sac,
the posterior-most chamber that collects the returning venous blood; (2) the atrium, also thin
walled, which appears smaller and angular when contracted and becomes the largest chamber
when it is distended with blood during diastole; (3) the ventricle, a thick-walled major contractile
part of the heart that is the largest chamber after systolic contraction; and (4) the conus arteriosus,
thick but narrow tubular part of the heart, which extends from the ventricle to the truncus arteriosus
(Kinoshita et al., 2009; Lemanski et al., 1975; Romer, 1956). Among the chambers, the ventricle
is extensively trabeculated, and the atrium is partly trabeculated; however, no trabeculation was
observed in the sinus venosus and conus arteriosus (Kinoshita et al., 2009). These trabeculae
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anastomose give the whole chamber a spongy appearance (Lemanski et al., 1975). The blood
enters into the sinus venosus part of the heart via the cardinal and hepatic veins, then travels into
the ventricle through the atrium. The blood moves into the ventral aorta through the conus
arteriosus by vigorous muscle contractions of the ventricle. From the ventral aorta, blood enters
into the gills where oxygenation occurs, and then it is distributed into rest of the body.
Walls of the heart: Like humans’, fish’s hearts consist of three distinct layers: epicardium
(outer layer), myocardium (middle layer), and endocardium (inner layer).
Epicardium: The epicardium, the outer layer of the heart, is a simple squamous epithelial
layer of cells connected by desmosome that form a tight continuous sheet over the exterior part
of the heart (Lemanski et al., 1975). The nuclei of the epicardial cells are oval in shape; cytoplasm
are flattened if observed in cross section. However, many of the cells in cytoplasm show branching
finger-like projections if they are observed in tangential sections. There are numerous rough
endoplasmic reticulums. The cisternae, which are ribosome-attached, are organized in a parallel
manner. Ribosomes are joined to the outer nuclear membrane in certain areas. However, there
are few free ribosomes and polysomal complex present in the cytoplasm. Golgi bodies and
vesicular elements are also present close to the nucleus. Moreover, there are abundant filaments
in the cell cytoplasm, which are randomly arranged and have a diameter of 60Å (Lemanski et al.,
1975).
Myocardium: The wall of the myocardium is a single cell layer, and each of the cells has
a nucleus that is basally located. There are abundant mitochondria across the myocardium, which
are centrally-located in the cells between the myofibrils, located peripherally. The large numbers
of mitochondria that are associated with the myofibrils provide the actively contracting heart its
increased demand of respiratory requirements. The rough endoplasmic reticulum, free
ribosomes, or polysomes are rarely seen in the cells. The fewer numbers of ribosomes and rough
endoplasmic reticulum indicate the paucity of activity in protein synthesis of these cells. Golgi
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bodies are also seldom seen in the myocardial cells, which further support the inadequacy of
protein synthesis, because this is used to collect and dispatch the protein, which are received
from the endoplasmic reticulum.
Endocardium: The endocardium consists of irregularly shaped cell lines inside the heart.
The nuclei look flattened to oval in cross section. The numbers of mitochondria are less, and
smaller in size than in the myocardial cells, which are present along with rough endoplasmic
reticulum and in close proximity. There are large numbers of ribosomes present in the cell. Golgi
bodies are present in the perinuclear regions of the cells, which are well developed and, contain
vesicular elements. These structures of the endocardial cells suggest that they are actively
involved with protein synthesis. However, the reasons for endocardial cells being active in protein
synthesis are not clear. The endocardial and myocardial cells have areas of confluent cytoplasm
in certain regions, which suggests the possibility that the endocardial cells are synthesizing
materials that are being used all or in part by the myocardial cells (Lemanski et al., 1975). So, the
endocardium of the medaka heart serves not only as a protective layer but also as metabolically
active group of cells.
1.6 Canonical Wnt/β-catenin Pathway
The Wnt1 gene, originally known as Int-1, was identified in 1982 in virally induced breast
tumors activated by integration of mouse mammary tumor virus proviral DNA (Nusse and Varmus,
1982; Clevers and Nusse, 2012). Other major parameters of this signaling pathway were identified
in Drosophila in 1994 including β-catenin, dishevelled (Dvl), and glycogen synthase kinase 3β
(GSK3β) gene (Noordemeer et al., 1994, Peifer et al., 1994, Siegfried et al., 1992). By 2000, the
Wnt receptor Frizzled (Fzd) and co-receptor lipoprotein receptor related (LRP5/6) protein and Wnt
nuclear effectors T cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors were
discovered (Behrens et al., 1996; Bhanot et al., 1996; Molenaar et al., 1996; Wehrli et al., 2000).
Since then, the Wnt/β-catenin pathway has played a significant role in unraveling many questions
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in developmental biology. Signaling by the Wnt family of secreted glycoproteins plays an
important role in embryonic development and homeostasis in adult tissue by cell differentiation,
cell proliferation, cell migration, cell polarity, and cell fate determination (Logan and Nusse, 2004;
Macdonald et al., 2009; Johnson and Rajamannan, 2006). Therefore, mutation in this pathway
can cause birth defects, cardiovascular abnormality, cancer, and even mortality (Clevers, 2006;
Cattelino et al., 2003). Wnt proteins signal through several pathways, of which the canonical Wnt
signaling pathway is the most studied and acts by regulating the co-activator β-catenin that
controls key developmental gene expression (Fig. 1.5) (Macdonald et al., 2009).
1.6.1 Role of canonical Wnt/β-catenin signaling in cardiac diseases
The canonical Wnt/β-catenin signaling pathway is involved with the regulation of
embryonic development and adult homeostasis (Macdonald et al., 2009). Blocking this pathway
during early differentiation is involved with inhibition of beating cardiomyocytes and early cardiac
markers, and slightly later activation is involved with inhibition of cardiac differentiation (Naito et
al., 2006). The Wnt/β-catenin pathway is also involved with regulation of endothelial cell (EC)
development; inhibition of β-catenin in developing EC can cause embryonic mortality and loss of
EC integrity (Cattelino et al., 2003). Moreover, EC specific β-catenin loss is involved with defective
endocardial cushion/cardiac valve development, and loss of a frizzled receptor (Fzd5) in mice has
been reported to produce defective vascular development and embryonic lethality (Cohen et al.,
2007; Ishikawa et al., 2001). Cohen et al. (2007) has mentioned a resemblance between defective
Wnt/β-catenin signaling pathway and human congenital heart disease. Previous studies have
shown the involvement of Wnt signaling with cardiac hypertrophy (Horst et al., 2012). Blankesteijn
et al. (1996) demonstrated that Fzd 2 was upregulated with cardiac hypertrophy in rat heart tissue
after aortic constriction (Blankesteijn et al., 1996). Another study showed upregulation of Dvl in
the case of aortic constriction in mice and rats (Van de Schans et al. 2007; Malekar et al. 2010).
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Activation of the canonical Wnt pathway was reported in epicardial fibrosis of failed
pediatric heart transplants (Ye et al., 2013). Deposition of fibrosis causes arrhythmias that result
from cardiac diseases and cardiac repair post myocardial infarction by disrupting electrical wave
propagation (Benito et al., 2011; Rohr, 2012). Wnt signaling is involved with heart failure by
inhibiting apoptosis through activation of Akt and inhibition of GSK3β (Haq et al., 2001). There is
conflicting evidence for the involvement of Wnt signaling in the pathogenesis of arrhythmogenic
cardiomyopathy (AC). Some studies show that suppression of Wnt signaling is involved with AC.
It was also demonstrated that AC can be caused by downregulation of the Wnt/β-catenin pathway
due to nuclear translocation of plankoglobin, homologous with β-catenin (Garcia-Gras et al., 2006;
Lombardi et al., 2009; Lombardi et al., 2011; Ben-Ze’ev et al., 2000). Due to the reduction of
desmoplakin expression in mouse hearts and cultured atrial myocytes, plakoglobin is released
from the cell membrane, which translocates into the nucleus, interferes with β-catenin/Tcf
transcriptional activity, and produces AC phenotypes (Garcia-Gras et al., 2006; Lorenzon et al.,
2017). Moreover, activation of the Hippo pathway regulates cellular differentiation and
proliferation decreased activation of Wnt signaling to induce AC (Lorenzon et al., 2017). Another
study showed that activation of GSK3β and suppression of AKT was able to cause exercisemediated AC phenotypes (Martherus et al., 2016). However, some contradictory evidence shows
over-activation of Wnt/β-catenin signaling due to β-catenin stabilization by AKT activation and
GSK3β inhibition can induce AC pathogenesis (Li et al., 2011).
1.6.2 Overview of canonical Wnt signaling
The Wnt/β-catenin signaling pathway is well characterized in the teleost fish model (Ueno
et al., 2006; Barjhoux et al., 2016). This pathway is triggered by Wnt family ligands, such as
secreted lipoglycoproteins that require the Fzd family receptors and co-receptor LRP 5/6 for
functional activity (Niehrs, 2012). In the absence of Wnt stimuli (resting state), β-catenin forms a
complex with GSK3β, casein kinase 1α (CK1α), adenomatous polyposis coli (APC) and axin,
known as the destruction complex (Fig. 1.5). The level of β-catenin is regulated by sequential
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phosphorylation by Ck1α at serine 45 and then by GSK3β at threonine 41, serine 37, and serine
33 (Kimelman and Xu, 2006). The phosphorylation of β-catenin at serine 33 and 37 forms a
binding site for E3 ubiquitin ligase β-Trcp, which leads to β-catenin ubiquitination and degradation
(Fig. 1.5) (Macdonald et al., 2009). This causes repression of Wnt target genes by DNA-bound
TCF/LEF through prevention of translocation of β-catenin into the nucleus (Fig. 1.5) . Fzd is linked
to the Dvl protein that is a cytoplasmic scaffolding protein directly interacting with Fzd (Macdonald
et al., 2009; Wallingford and Habas, 2005; Wong et al., 2003). Dvl interacting with Axin is required
during Wg signaling for Axin translocation to the plasma membrane or in case of Fzd
overexpression (Cliffe at al., 2003; Zeng et al., 2008; Wallingford and Habas, 2005). A previous
study showed that Fzd-Dvl recruitment of the Axin-GSK3 complex triggers GSK3 mediated LRP6
phosphorylation (Zeng et al., 2008). When Wnt ligands are present, they interact with the Fzd
receptor and co-receptor LRP5/6, which results in activation of the Dvl protein (Fig. 1.5) (Billic et
al., 2007). Recruitment of Dvl protein causes phosphorylation of LRP5/6 and translocation of Axin
to the receptor, which inhibits degradation of β-catenin by dissociating the destruction complex
(Fig. 1.5). This allows β-catenin to accumulate in the cytosol and translocate into the nucleus,
which forms a complex with TCF/LEF and activate expression of Wnt responsive genes (Fig. 1.5)
(Macdonald et al., 2009).
Dickkopf proteins (DKK) are inhibitors for Wnt/β-catenin signaling that bind to LRP5/6 with
high affinity (Ahn et al., 2011; Bourhis et al., 2010; Niehrs, 2006). Deletion of DKK1 results in
embryonic lethality and developmental abnormality such as loss of anterior head structure and
fused vertebrate in mice model (Mukhopadhyay et al., 2001). DKK1 inhibits Wnt signaling by
inducing LRP5/6 internalization/ degradation through binding to the cell surface receptor Kremen
(Krm) (Mao et al., 2002). The probable mechanism might be disruption of the Wnt-induced FzdLRP5/6 complex by DKK1 with a minor modulatory role of Krm (Ellwanger et al., 2008; Semenov
et al., 2001). DKK1 directly competes with Wnt for binding sites on LRP5/6, and inhibit Wnt
signaling (Ahn et al., 2011).
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Wnt off-state

Wnt on-state

Figure 1.5: Overview of Wnt Signaling: Wnt on/ off state. Wnt off state: In the absence of Wnt,
cytoplasmic β-catenin forms a complex with axin, APC, GSK3, and CK1. β-catenin is
phosphorylated by CK1 and GSK3, which results in its ubiquitination by an E3 ubiquitin ligase
protein β-Trcp and proteasomal degradation. This causes repression of Wnt target genes by DNAbound TCF/LEF through prevention of translocation of β-catenin into the nucleus. Wnt on state:
In the presence of Wnt, a complex is formed with the Fzd receptor and co-receptor, LRP5/6.
Recruitment of Dvl protein causes phosphorylation of LRP5/6 and translocation of axin to the
receptor that inhibits degradation of β-catenin. Therefore, β-catenin translocates to the nucleus
to form a complex with TCF/LEF and activates Wnt-responsive genes. (He et al., 2004;
Macdonald et al., 2009; Lorenzon et al., 2017)
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1.6.3 Non-canonical Wnt pathway
The non-canonical Wnt pathway is β-catenin-independent and uses downstream
components of the pathway other than β-catenin-TCF/LEF. The planar cell polarity (PCP)
pathway is the best characterized non-canonical pathway in which the Fzd receptor triggers a
cascade of downstream effectors, including RAC1 (small GTPase), small GTPase, Ras homolog
gene family, member A (RHOA), and c-Jun N-terminal kinase (JNK), which regulate
rearrangement in the cytoskeleton and gene expression (Gomez-Orte et al., 2013). This pathway
controls cell polarity in morphogenetic processes including gastrulation, neural tube closure, and
stereocilia orientation in the inner ear (Axelrod, 2009; Gomez-Orte et al., 2013; Kikuchi et al.,
2011; Simons and Mlodzik, 2008). Another non-canonical Wnt pathway is the Wnt-Ca 2+ signaling
pathway where Wnt elicits Fzd-regulated activation of heterotrimeric G protein that results in
activation of phospholipase C (PLC). Ultimately, PLC causes the release of Ca2+ from intracellular
storage and activation of effectors that control transcription of the factors involved with regulation
of cell fate and cell migration (Gomez-Orte et al., 2013). The Wnt-Ca2+ non-canonical pathway is
involved with cancer, inflammation, and neurodegeneration (Axelrod, 2009; De, 2011; GomezOrte et al., 2013; Kikuchi et al., 2011; Niehrs, 2012; Macdonald et al., 2009; Simons and Mlodzik,
2008).
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1.7 Specific Aims:

The objective of our study was to determine the teratogenic potential of 4-Omethylhonokiol (MH) on Japanese medaka and to elucidate the mechanisms which triggered this
effect. MH is a major bioactive constituent of Magnolia grandiflora seeds or Magnolia officinalis
bark. Magnolia genus has been widely reported to have various beneficial effects on the
cardiovascular system, including anti-atherosclerosis, vascular relaxation, and antiplatelet effects
(Zhao et al., 2016). MH has been proven to be successful against high-fat diet-induced cardiac
pathogenic changes (Zhang et al., 2015). However, the effect of this compound on the
cardiovascular system during embryogenesis hasn’t been characterized yet and our preliminary
study showed that the compound had produced some adverse effects by slowing heartbeat,
forming thrombus, preventing vessel circulation and hatching efficiency and causing mortality
during embryogenesis. Our preliminary data also showed this compound caused some birth
defects and had an effect on survivability 1 month after fertilization. Therefore, it would be
beneficial if the teratogenic potential of MH, a structural analog of honokiol and mechanistic study
associated with it could be identified on Japanese medaka in a time- and concentrationdependent manner.

Aim 1: To determine the teratogenic potential of MH on Japanese medaka:
1a. Determination of MH effect on medaka embryogenesis:
Hypothesis: MH will cause teratogenic potential in medaka embryos in a time- and
concentration-dependent

manner.

Approach:

Embryos

will

be

treated

with

different

concentrations of MH throughout embryonic stage 10 to 38 (0-6 day post fertilization, dpf) and
after the vessel circulation starts (stage 25-38/2-6 dpf) to observe if the compound can cause any
changes in their function and survivability.
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1b. Effect of MH on locomotion and survivability of medaka:
Hypothesis: MH has an effect on locomotion and survivability in larval and adult stage of
the exposed embryos. Approach: Embryos will be treated with sublethal concentrations of MH
from stage 10 to 38 (0-6 dpf). The 2 dph larvae will be weighed and used for locomotion study.
They will be grown into 30 dpf fish to observe the effect of the compound on locomotion and
survivability.
1c. Impact of MH on the components of the blood coagulation pathway and on
proinflammatory mediators:
Hypothesis: MH will activate components of coagulation factors or block the fibrinolytic
system to promote thrombosis. However, thrombus may be caused by other consequences, such
as damaged blood vessels due to an excessive inflammatory response or oxidative stress.
Approach: Effect of MH will be evaluated on some major components of the blood coagulation
pathway or on the fibrinolytic pathway. The gene expression of inflammatory mediators and
antioxidant enzymes will be determined by RT-qPCR. The level of reactive oxygen species (ROS)
will be measured using 2′, 7′-dichlorodihydro-fluorescein diacetate (DCHFDA).
Aim 2: To characterize the Wnt/β-catenin signaling pathway as a potential mechanism of
embryonic abnormality induced by MH:
Hypothesis: MH will block the Wnt/β-catenin signaling pathway to prompt embryonic
abnormality because this pathway is known to control embryonic development, cardiac and
endothelial cell development during embryogenesis. Moreover, blockade of this pathway is known
to cause birth defects. Approach: We will analyze the expression of the major parameters of this
pathway, including Wnt, β-catenin, inhibitor of Wnt (DKK1) and receptors (LRP-5, Frizzled) of Wnt
in both control and treated embryos (MH treatment during stage10-38/0-6 dpf).
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Upon successful completion of this study, we will be able to determine the concentrationand time-dependent teratogenic potential of MH which has been reported previously to have
diverse biological activities. Moreover, the mechanistic study of inducing these effects will be
helpful to unravel therapeutic strategies to prevent these consequences. This study is relevant
because it will characterize for the first time effect of MH on embryogenesis, especially on the
development of the cardiovascular system.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Animal maintenance and egg collection
Orange-red variety of Japanese medaka (Oryzias latipes) originally purchased from
Carolina Biological (Burlington, NC) were maintained in the fish culture facility for more than 20
years. The fish were maintained with balanced salt solution (BSS, 17mM NaCl, 0.4mM KCl,
0.3mM MgSO4, 0.3 mM CaCl2, pH 7.4) in an Aquatic Habitats ZF0601 Zebrafish Stand-Alone
system (Aquatic Habitats, Apoka, FL) at 26±10C, 16L: 8D light cycle, salinity 1.2 and pH 7.4
(Dasmahapatra et al., 2017). Fish were fed with a combination of Tetramin flakes (Tetra,
Blacksburg, VA) and live brine shrimp (Brine Shrimp Direct, Ogden, UT) twice a day. Fertilized
eggs were collected from the reproductively active adult female medaka fish and screened for
viability.

2.2 Determination of the effect of MH on medaka embryogenesis
The objective of this study was to evaluate the effect of MH on medaka embryogenesis in
a concentration- and time-dependent manner. Fertilized medaka eggs (n=5 independent
exposure, each exposure had 12 embryos) (Iwamatsu stage 10) were exposed to MH (0, 1, 2, 5,
10, 20 µM) in hatching solution (17 mM NaCl, 0.4 mM KCl, 0.3 mM MgSO4, 0.3 mM CaCl2, with
required amount of NaHCO3 to maintain the pH 7.4 and 0.0002% methylene blue to reduce fungal
infection) in a 48-well culture plate (one embryo/ml/well) and maintained in a high performance
incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 26±1°C (Dasmahapatra et al., 2017).
The treatment was continued for 6 days (0-6 days post fertilization-dpf) at 0, 1, 2, 5, 10, and 20

M concentrations and 4 days (2-6 dpf) at 0, 1, 2, 5, 10, and 20 M concentrations; the control

28

embryos were maintained in 1 ml hatching solution (0.02-0.04% DMSO). After the removal of MH,
the embryos were maintained in hatching solution from 6 dpf and continued until 10 dpf with 50%
static media change. Heartbeats were counted for 1 minute during 3 dpf and 6 dpf under the
phase contrast microscope. Vessel circulation and thrombus formation was also observed, and
photographs were taken under a light microscope attached to a Cannon DC 7.4 V camera. Vessel
circulation, hatching efficiency, and mortality were observed under the phase contrast microscope
(AO Scientific Instruments, Buffalo, NY). The LC50 was calculated at 10 dpf. The photographs of
the heart were taken by Eclipse Ti2 inverted microscope system (Nikon Instruments Inc., Melville,
NY).

2.3 RNA extraction, cDNA synthesis, and RT-qPCR
Fertilized embryos (Iwamatsu stage 10) (n=4, 100 embryos/pool) were treated with 10 µM
MH for 0-6 dpf. The control group was maintained in 50 ml of hatching solution with 0.01% of
DMSO. Both groups were homogenized at 6 dpf in 1 ml of trizol (Invitrogen, Carlsbad, CA) for 6
minutes (30 seconds running and 30 seconds in ice for three times). Then they were kept in a 20ºC freezer overnight, and then thawed, and 200 µl chloroform was added. It was shaken 15 sec
by hand, incubated at 15-30ºC for 2-3 min and centrifuged for 15 min at 6ºC. The upper colorless
aqueous phase which contained the RNA was transferred to a fresh tube. Isopropyl alcohol (500
µl) was added, incubated at room temperature, and centrifuged for 10 min at 6ºC. The supernatant
was removed and 1 ml of 75% ethanol was added, vortexed, and centrifuged for 5 min at 6ºC.
Again, the supernatant was removed and the tube was air dried for 5-10 min in a way that the
RNA did not dry completely. RNase free water (100 µl) and 350µl buffer RLT (QIAGEN Sciences,
MD) with β-ME (9:1) were added and mixed thoroughly. Then ethanol (100%) was added, mixed
thoroughly by pipetting, and 500 µl sample was transferred to a column of a collection tube. Tubes
were centrifuged for 15 sec and the flow-through was poured out. The rest of the sample was
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transferred to the column, centrifuged, and poured out in the same way. Then 500 µl RPE buffer
(QIAGEN Sciences, MD) was added to the column and centrifuged for 2 min. The column was
transferred to a new collection tube, and RNase free water was added to the column and
centrifuged for 1 min. The RNA concentration was measured in a NanoDrop (Thermo Scientific,
Wilmington, DE).
RNA was reverse transcribed to cDNA following manufacturer’s protocol by iScript
supermix (BioRad Laboratories, Hercules, CA) in a 20 µl final volume. The complete reaction was
incubated in a thermal cycler for priming at 25ºC for 5 min, reverse transcription at 46ºC for 20
min, and RT inactivation at 95ºC (BioRad Laboratories, Hercules, CA). RT-qPCR was performed
with the following protocol (BioRad Laboratories, Hercules, CA): polymerase activation and DNA
denaturation at 95ºC for 3 min, followed by 40 cycles of denaturation at 95ºC, 10 sec, and
annealing at 60ºC, 30 sec followed by thermal dissociation protocol for SYBR green detection.
The target gene was normalized to a corresponding housekeeping gene, elf-1α. McCurley and
Callard, (2008) performed an experiment with eight housekeeping genes, including bactin1,
tuba1, gapdh, g6pd, tbp, b2m, elf1α, 18s rRNA to measure their variability during development,
across different tissue types, and with chemical/toxicant exposure in zebrafish. The gene, elf1α
showed low degree of variability compared to the other genes under all conditions (McCurley AT,
Callard GV, 2008). Fold change was determined by relative quantification method (∆∆Ct method).
The quality of the RT-qPCR product was evaluated on a 2% agarose gel containing 0.01%
ethidium bromide.
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Table 2.1: List of primers
Gene

Sense (5/-3/)

Antisense (3/-5/)

elf1α

GGAGGCCAGCGACAAG
AT

GCGAGAAGGTGGCAGG
AT

FX

TGTCAAAGCCCTGTGTG
AAT
GAAGGATAATGCAGACC
AGTGTC

Product
size
(bp)
115

Reference

AGAAATGTTCACAGCCA
CCA
GATGACACCCTTCAAGT
AGCATC

147

XM_0207
10825.1
XM_0040
74394.4

GTTCTGTCGGATAGGTG
GATTT
ATGCCGAGGTTTTCTCT
GAAC
ACTGTGTTTCTGGGAAA
GAGTG
CAGCCCCGATCCAAGC

CCTCCAGGTCATGTTTA
CCTAC
GTTGAACATGTCTCCCA
GTCC
GGATGATCATTTTCTCC
ACGGT
CCCTTCCATCGCAGCC

97

ATRAP

CATGTGGGGGAACTTCA
GC

GCCCACCAGAAACATGA
GG

91

ETB

CTGATCTTTGTGGTGGG
CAT

CCCATTCCTCATGCACT
TGT

78

NM_0011
04844.1

IL-1β

CTGTTTCTGGAGGAGGT
GG

AGAAGAGGAAGCGCAC
ATT

79

XM_0114
78737.2

TNF-α

AACCGAAGAGTCTGAGA
GGG

AGCTGAAGAAGAGTACC
GCT

105

XM_0040
74335.3

CAT

TGCTAGCAGTTGATTGT
CTGT

CACAGATCCACTGAAAC
AGGA

100

XM_0040
69460.2

GPX2

TCAACGGAGTAAACACG
CAT

GATCCTGCATGAGAGAG
CTG

90

XM_0040
82594.3

GST A

CTGAAGGAGAGCGGCA
C

CAGGAACGAGCCAGAG
C

107

XM_0207
10769.1

SOD2

AAATGTGCGTCCTGACT
ATGT

TTTTGGCTATCTGAAGA
CGCT

83

XM_0040
83471.3

Wnt1

CCAGAAAACCCAGCTCA
CAA

TTGTGGGAGCAGAAGTT
TGG

80

XM_0207
04658.1

FXI
FVII
PAI-1
uPA
tPA
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127

78
82
185

NM_0011
04662.1

XM_0040
66449.3
XM_0207
11407.1
XM_0040
77409.4
XM_0114
78844.3
XM_0114
75678.2

FZd2

CACATGACCCCAGACTT
CAC

AGAAACCAGAAGTGATG
CCG

76

XM_0207
05151.1

LRP5

GAAGGCCCGAGCAGTT
CA

AAGACATGGCTCCGTCG
T

101

XM_0114
72833.2

Dvl

TGCTGAAACAAAGCCCA
AAGT
CACAGAACTCCTACACA
GCC

ACCTCAAGGATCTGAGT
GAGC
AGGCGCTTCTTGTAGTC
TTG

87

XM_0114
90628.3
XM_0040
77778.3

DKK1

GTGACACATGCCTGAGA
TCG

CACAGGCTTACAGATGC
GAG

83

XM_0207
09512.1

GSK3β

AGCTGCAGATTATGAGG
AAGTTG

TAGACGGTCTCTGGAAC
ATAGTC

130

XM_0239
50884.1

ErbB3

GAGGTTGAGAAGGATG
GCGT

CTACCTGGACTTCCTGT
GCC

86

XM_0114
74665.3

NRG-2

CTCGTCACTGTGGGGG
A

CTCGTCAGTGGGGTCCA

93

XM_0207
08867.2

BNP A

GAGCTCTGTTGATGAGG
AGG

CAGTCCTGGCTCATCTT
CTC

88

NM_0011
04685.2

cTnT

CAGAGAGGGAAAGGGA
ACG

GCTGATCCGGTTTCTGA
GT

362

XM_0040
68713.4

FoxO1

GCCCATGCCAGTTCTGA
GTA

ATCCTCCGTGTTGGTGG
ATG

102

XM_0114
85361.2

β-catenin
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102

2.4 Effect of MH on locomotion
The aim of this method is to evaluate the role of MH on locomotion of the hatched embryo
(larvae). The embryos (n=14-16) were treated with sub lethal concentration of MH (0, 5 µM) during
0-6 dpf. At 2 days post hatching (dph), the larvae were placed in a 24-well plate with a single fish
per well containing 2 ml hatching solution for a locomotion assay. They were placed in the
darkness of the Zebrabox for 20 min (Viewpoint, Montreal, Canada) to achieve the basal
swimming activity (Bihanic et al., 2015) and monitored every 2 min for a 20 minutes cycle (10 min
in the dark followed by 10 min in light). This cycle was repeated twice. The assay was performed
between 1:00 pm and 4:00 pm, which is the optimal time interval for obtaining the stability of the
basal activity (Chiffre et al., 2016). The duration of movements was measured at a velocity of ≥2
mm/sec. Data were analyzed by two-way ANOVA followed by a Bonferroni post-hoc test. Each
value represents the mean ± SEM of 14-16 observations.

2.5 UHPLC/MS Analysis
This experiment was designed to confirm whether MH infiltrated into the embryonic
tissues. It was performed on an Agilent 1290 Infinity liquid chromatograph coupled with an Agilent
6120 single quadrupole mass spectrometer. The chromatographic column was a Waters Acquity
UPLCTM BEH RP-C18 column (1.7µm, 2.1 x 150mm). The mobile phase consisted of A (water with
0.05% formic acid) and B (acetonitrile with 0.05% formic acid) at a flow rate of 0.3 mL/min. The
gradient elution started with 50% A, and then it was linearly increased to 100% A in 6 min and
held for 2 min. The column temperature was maintained at 30ºC. A standard curve was prepared
with MH in the range of 1.8 µM to 35.7 µM concentrations. Two wavelengths, 210 and 254 nm,
were monitored for the DAD detector. MH was analyzed by ESI and APCI in both positive and
negative modes. APCI positive mode was selected for the analysis because it produced a better
ion signal for MH than other ionization modes. The drying gas flow was 10 L/min, and the nebulizer
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pressure was 30 psi. The drying gas temperature and vaporizer temperature were set to 250ºC
and 200ºC, respectively. The capillary voltage was 4000 V and the corona current was 4.0 µA.
The MS was operated in both scan and selected ion monitoring (SIM) mode. [M+H]+ 281 was
selected to monitor the targeted compounds.

2.6 Statistics
Results were expressed as Mean ± SEM. Morphological data (0-6 dpf and 2-6 dpf
exposure of MH at 0, 1, 2, 5, 10, 20 µM concentrations) (n=5 independent exposure, each
exposure had 12 embryos) were analyzed by one way ANOVA followed by Tukey's post-hoc
multiple comparison test. The LC50 was calculated by log transformed data using nonlinear
regression (Curve-fit) (Graph pad Prism). Statistical analysis for all RT-qPCR data (0-6 dpf
exposure of MH at 0, 10 µM concentrations) (n=4, 100 embryos/pool) was performed by nonparametric t-test followed by unpaired-t test. Data for locomotion study (0-6 dpf exposure of MH
at 0, 5 µM concentrations) (14-16 observations) were analyzed by two-way ANOVA followed by
Bonferroni post-hoc test. Statistical significance was defined as p<0.05.

34

CHAPTER 3: RESULTS
3.1 Effect of MH exposure throughout all of the embryonic development (0-6 dpf) on
survival and function
This experiment was designed to observe whether MH exerted any effect if treated during
embryogenesis (0-6 dpf). The morphological parameters, such as survivability, hatching
efficiency, and cardiovascular parameters, such as heart beat, and blood circulation were
evaluated.

3.1.1 Effect of MH on survivability of medaka embryos
Fertilized medaka eggs (n=5 independent exposure, each exposure had 12 embryos) of
Iwamatsu stage 10 were exposed to different concentrations of MH (0, 1, 2, 5, 10, 20 µM) for 6
days (0-6 dpf). The effect of MH was evaluated on the survivability of medaka embryos, and the
LC50 was also calculated (Fig. 3.1). MH caused an increased trend in mortality from 7 dpf until 10
dpf with 10 µM exposure. It showed about 80% mortality in 10 dpf. The highest concentration of
MH (20 µM) caused 75% mortality by 4 dpf and showed 100% cumulative mortality by 10 dpf.
MH, 5 µM caused 20% mortality at 10 dpf (Fig. 3.1). However, lower concentrations (1, 2 µM) did
not produce significant mortality (Fig. 3.1). The calculated LC50 was observed to be 5.3 ± 0.1 µM
(Fig. 3.1).
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Figure 3.1: Cumulative mortality of medaka embryos. Embryos were exposed to 1, 2, 5, 10,
and 20 M of MH for 0-6 dpf. The effect on cumulative mortality (Panel A) was assessed until 10
dpf. Each value represents mean ± SEM. (n=5 independent exposure, each exposure had 12
embryos). The LC (Panel B) was calculated by log transformed data using nonlinear regression
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(Curve-fit) (Graph pad Prism).
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3.1.2 Impact of MH on hatching efficiency of medaka embryos
Hatching efficiency was significantly decreased with 0-6 dpf 10 µM MH exposure
compared to the control group at 10 dpf (Fig 3.2). Other treatment groups (1, 2, 5 µM) did not
show any significant change in hatching efficiency (Fig 3.2).
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Figure 3.2: Hatching efficiency of medaka embryos. MH (10 µM) significantly prevented
hatching efficiency compared to the control until 10 dpf. Each value represents the mean ± SEM
(n=5 independent exposure, each exposure had 12 embryos). Statistical analysis was performed
by one-way ANOVA followed by Tukey’s post-hoc multiple comparison test. p<0.05 was
considered as significant. The asterisk (*) represent the values are significantly different from
control.
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3.1.3 Effect of MH on homeostasis
MH also affected blood circulation in a concentration-dependent manner. In the highest
concentration (10 µM), MH stopped circulation and thrombi formation was a consequence (Fig
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A

Thrmobi formation (% Embryos)

100

0

Circulation cessation (% Embryos)

3.3). Representative images are shown in Fig 3.4.

MH (M)

Figure 3.3: Blood circulation cessation and thrombus formation in medaka embryos. MH
(10 µM) significantly ceased blood circulation (Panel A) and caused induction of thrombi formation
(Panel B) until 10 dpf. Bars represent mean ± SEM (n=5 independent exposure, each exposure
had 12 embryos). Analysis was performed by one-way ANOVA followed by Tukey’s post-hoc
multiple comparison test. p<0.05 was considered as significant. The asterisk (*) represents the
value is significantly different from control.

A

B

Figure 3.4: Representative thrombus generation by MH. The photographs were taken under
the light microscope attached to a Cannon DC 7.4 V camera. Panel A represents the control
group, and panel B represents thrombus formation (red arrow) in 10 M treatment groups
38

3.1.4 Impact of MH on heart beat
Embryos were exposed to 2, 5, and 10 M of MH for 0-6 dpf, and heartbeats were counted
for 1 minute at 3 dpf and 6 dpf (Table 3.1). MH exposure was not able to cause any change in
heart beat by 3 dpf. However, 10 µM MH treatment decreased the heart beat significantly at 6 dpf
compared to the 6 dpf control group. The other treatment groups did not show any significant
change in heartbeat (Table 3.1).

Table 3.1: Effect of MH on heartbeat of medaka embryos on both 3 dpf and 6 dpf
Treatment
groups (µM)

Heartbeat/min
3 dpf
(Mean ± SEM)

6 dpf
(Mean ± SEM)

0

105±2

117±1

2

103±3

115±2

5

10

115±1

106±2
103±2

107±2*

Each value represents the mean ± SEM (n=3 independent exposure, each exposure had 12
embryos). The asterisk (*) represents value is significant versus the corresponding control group
(p<0.05). Data analysis was performed by one-way ANOVA followed by Tukey’s post-hoc multiple
comparison test.
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3.2 Effect of MH exposure on embryos following circulation (2-6 dpf) on survival and
function
This study was designed to observe whether MH caused any effect on medaka embryos
when they were treated after the onset of blood circulation. The same parameters were also
evaluated here as the previous experiments.
3.2.1 Impact of MH on survivability of medaka embryos
When embryos were treated following onset of circulation (2-6 dpf), 10 µM MH caused
35% mortality at 9 dpf and about 50% mortality in 10 dpf (Fig 3.5). Treatment with higher
concentrations (20 µM) caused 58% mortality at 8 dpf, and 100% by 10 dpf. The LC 50 was
calculated to be 9.9 ± 0.2 µM (Fig 3.5).
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Figure 3.5: Cumulative mortality of medaka embryos. Embryos were exposed to 1, 2, 5, 10,
and 20 M of MH for 2-6 dpf. The effect on cumulative mortality (Panel A) was assessed until 10
dpf. Each value represents the mean ± SEM (n=5 independent exposure, each exposure had 12
embryos). The LC (Panel B) was calculated by log transformed data using nonlinear regression
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(Curve-fit) (Graph pad Prism).
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3.2.2 Impact of MH on hatching efficiency of medaka embryos
Hatching efficiency was significantly decreased with 10 µM MH exposure for 4 days (2-6
dpf) compared to the control group until 10 dpf (Fig 3.6). Other treatment groups (2, 5 µM) did not
show any significant change in hatching efficiency.
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Figure 3.6: Hatching efficiency of medaka embryos. MH (10 µM) significantly prevented
hatching efficiency compared to control at 10 dpf. Statistical analysis was performed by one-way
ANOVA followed by Tukey’s post-hoc multiple comparison test. p<0.05 was considered
significant. The asterisk (*) represents that the values are significantly different from the control
group. Bars represent mean ± SEM (n=5 independent exposure, each exposure had 12 embryos).
3.2.3 Effect of MH on homeostasis
Due to treatment with 10 µM MH for 4 days (2-6 dpf), blood circulation ceased and
thrombus was generated significantly compared to the control group (Fig 3.7). The other groups
(2, 5 µM) did not cause any significant change in terms of blood circulation and thrombus
formation. Representative images are shown in Fig 3.8.
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Figure 3.7: Blood circulation cessation and thrombus formation in medaka embryos. MH
(10 M) significantly ceased blood circulation (Panel A), and caused induction of thrombi
formation (Panel B) until 10 dpf. Analysis was performed by one-way ANOVA followed by Tukey’s
post-hoc multiple comparison test. p<0.05 was considered significant. The asterisk (*) represents
the value is significantly different from control. Bars indicates mean ± SEM (n=5 independent
exposure, each exposure had 12 embryos).

A

B

Figure 3.8: Representative thrombus formation induced by MH. Fertilized eggs were exposed
to 1, 2, 5, and 10 M of MH for 4 days (2-6 dpf), and the photographs were taken under the light
microscope attached to a Cannon DC 7.4 V camera. Panel A represents the control group, and
panel B represents thrombus formation (red arrow) in 10 M treatment groups.
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3.2.4 Impact of MH on heart beat
Embryos were exposed to 2, 5, and 10 M of MH for 2-6 dpf, and heartbeats were counted
for 1 minute during 3 dpf and 6 dpf (Table 3.2). MH exposure did not cause any change in heart
beat in 3 dpf compared to the control group. However, 10 µM MH treatment decreased the heart
beat significantly in 6 dpf compared to control group. The other treatment groups did not show
any significant change in heartbeat (Table 3.2).

Table 3.2: Effect of MH on heartbeat of medaka embryos on both 3 dpf and 6 dpf

Treatment
groups (µM)

Heartbeat/min
3 dpf
(Mean ± SEM)

6 dpf
(Mean ± SEM)

0

116±6

131±3

2

117±6

134±6

5

114±5

125±5

10

112±5

120±3*

Each value represents mean ± SEM (n=3 independent exposure, each exposure had 12
embryos). Data analysis was performed by one-way ANOVA followed by Tukey’s post-hoc
multiple comparison test. The asterisk (*) represents value is significant compared to the control
group (p<0.05).
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3.3 Effect of MH on major components of blood coagulation pathway
This experiment was designed to evaluate the expression of major components in the
blood coagulation pathway to explore MH-induced blood vessel occlusion during medaka
embryogenesis. Following exposure of MH throughout the whole embryonic period (0-6 dpf), the
embryos were screened for gene expression of major components in the blood coagulation
pathway (FVII, FX, FXI). Each experiment consisted of 100 embryos and experiments were
repeated for 4 times. Embryos were treated for 6 days (0-6 dpf) with 0 or 10 µM of MH. Total RNA
was extracted from both groups at 6 dpf, and reverse transcribed to cDNA and used for RT-qPCR
analysis utilizing FX, FXI, and FVII gene-specific primers. Gene expression of FX (1.8 fold), and
FXI (1.6 fold) was increased significantly due to 10 µM treatment with MH compared to the control
group (Fig. 3.9). FVII is a major component of the extrinsic blood coagulation pathway. FVII was
differentially up-regulated (1.5 fold) for 10 µM treatment with MH compared to the control group
(Fig. 3.9).
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Figure 3.9: Gene expression of FXI, FVII, and FX. Differential expression by RT-qPCR
normalized to elf-1α following exposure to 0 and 10 M of MH for 0-6 dpf. The groups were
analyzed using the 2-ΔΔCT method and analyzed by non-parametric t-test followed by unpaired-t
test (n=4, 100 embryos/pool). The asterisk (*) represents that the value is significant versus the
control group (p<0.05).
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3.4 Impact of MH on the fibrinolytic system:
This study was designed to evaluate the effect of MH on the fibrinolytic system. The effect
of the compound was characterized on the inhibitor of the pathway, PAI-1 that inhibits the
conversion of plasminogen to plasmin and the activators (tPA, uPA), which catalyzes the
conversion into plasmin. MH increased the expression of PAI-1 (1.6 fold), and uPA (1.8 fold)
significantly, however it did not change the expression of tPA (Fig. 3.10). The ratio of fold
differences between tPA and PAI-1 is 0.6 (Table 3.3).

A

B

PAI-1

2.5

*

2.5

2.0

*

2.0

Fold change

1.5
1.0
0.5

1.5
1.0
0.5

0.0

0

0

10

0.0
10

Fold change

uPA

MH (M)

MH (M)

tPA

C

Fold change

2.0
1.5
1.0
0.5

0

10

0.0

MH (M)

Figure 3.10: Gene expression of PAI-1, uPA, and tPA. Following MH exposure embryos were
used for RT-qPCR analysis utilizing PAI-1 gene-specific primer. Each value represents mean ±
SEM (n=4 pools, 100 embryos/pool). Data analysis was performed by non-parametric t-test
followed by unpaired-t test. The asterisk (*) represents value is significant versus the control group
(p<0.05).
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Table 3.3: Ratio between the fold differences of the activators and inhibitor of the
fibrinolytic system
Activator/Inhibitor

Ratio of fold differences

uPA/PAI-1

1.2

tPA/PAI-1

0.6
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3.5 Impact of MH on anti-oxidant enzymes
The expression of the anti-oxidant enzymes, Catalase (CAT), Glutathione peroxidase 2
(GPX 2), Glutathione S-transferase A (GST A), and Super-oxide dismutase 2 (SOD 2) were
evaluated in the MH (10 µM) treated embryos to evaluate the effect of the compound on oxidative
stress. MH increased the expression of CAT (1.8 fold), GPX 2 (1.9 fold), GST A (1.8 fold) (Fig.
3.11). Transcription factors of the forkhead box, class O1 (FoxO1) promote cellular antioxidant
defense, thus act as a regulator of the cellular stress (Klotz et al., 2015). MH increases the
expression of FoxO1 (1.9 fold) (Fig. 3.12).
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Figure 3.11: Gene expression of anti-oxidant enzymes (CAT, GPX 2, GST A, and SOD 2).
Each value represents mean ± SEM (n= 4 pools, 100 embryos/pool). The groups were normalized
to elf-1α and analyzed using the 2-ΔΔCT method. Data analysis was performed by non-parametric
t-test followed by unpaired-t test. The asterisk (*) represents value is significant against the control
group (p<0.05).
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Figure 3.12: Gene expression of FoxO1. Each value represents mean ± SEM (n=4, 100
embryos/pool). The groups were normalized to elf-1α and analyzed using the 2 -ΔΔCT method. Data
analysis was performed by non-parametric t-test followed by unpaired-t test. The asterisk (*)
represents value is significant compared to the control group (p<0.05).
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3.6 Effect of MH on blood vessels
The goal of this study was to observe the effect of MH on the major receptors in the blood
vessels to explain vasoconstriction, such as endothelin B (ET B), Angiotensin 2 receptor
associated protein (ATRAP). ETB is produced in response to elevated production of ET 1. ATRAP
interacts with angiotensin 2 type 1 receptor (AT 1R). MH increased expression of ETB (1.4 fold),
although did not cause any change in ATRAP expression (Fig. 3.13).
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Figure 3.13: Gene expression of ATRAP and ETB. Each value represents mean ± SEM (n=4,
100 embryos/pool). The groups were normalized to elf-1α and analyzed using the 2-ΔΔCT method.
Data analysis was performed by non-parametric t-test followed by unpaired-t test. The asterisk
(*) represents value is significant compared to the control group (p<0.05).
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3.7 Impact of MH on cardiac development
The goal of this study was to evaluate the effect of MH on neuregulin-2 (NRG-2) and
erythroblastic leukemia viral oncogene homolog (ErbB) 3 receptor tyrosine kinase to clarify the
compound’s role in cardiac development. ErbB3 signaling is critical for normal heart development
(Britto et al., 2004). We also evaluated gene expression of NRG-2 that is also expressed in the
endothelial lining of the atrium during development (Carraway et al., 1997) and NRG-2 knockout
mice manifests severe growth retardation and mortality (Britto et al., 2004). MH decreased the
expression of NRG-2 (0.5 fold) and ErbB3 (0.5 fold) compared to the control group (Fig. 3.14).
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Figure 3.14: Gene expression of NRG-2, ErbB3. Each value represents mean ± SEM (n= 4
pools, 100 embryos in each pool). Data analysis was performed by non-parametric t-test followed
by unpaired-t test. The asterisk (*) represents value is significant versus control group (p<0.05).
The groups were normalized to elf-1α and analyzed using the 2-ΔΔCT method.
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3.8 Effect of MH on cardiovascular markers
Two major cardiovascular markers, such as cardiac troponin T (cTnT), Brain natriuretic
peptide A (BNP A) representative of myocardial injury were evaluated to confirm MH-induced
cardiovascular abnormality. MH increased the expression of cTnT and BNP A by 2.4, and 2.5
fold, respectively (Fig 3.15).
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Figure 3.15: Gene expression of cTnT, and BNP A. Each value represents mean ± SEM (n=
4, 100 embryos/pool). Data analysis was done by non-parametric t-test followed by unpaired-t
test. The asterisk (*) represents value is significant versus the control group (p<0.05). The groups
were normalized to elf-1α and analyzed using the 2-ΔΔCT method.
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3.9 Effect of MH on the major components of the Wnt/β-catenin signaling pathway
This study was performed to observe whether MH could affect the major components of
the Wnt/β-catenin pathway inducing any cardiovascular abnormality. The differential expression
of major upstream and downstream components of the Wnt/β-signaling pathway were evaluated
following an exposure of 10 µM MH for 0-6 dpf. MH upregulated the expression of Wnt1 (2.1 fold),
Fzd 2 (1.6 fold), LRP 5 (1.6 fold), Dvl (1.7 fold), β-catenin (1.9 fold), DKK1 (2 fold) (Fig. 3.16). The
expression of GSK-3β was not increased due to exposure of 10 µM MH (Fig. 3.16).
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Figure 3.16: Gene expression of major components of the Wnt/β-catenin pathway.
Differential expression of Wnt 1, Fzd 2, LRP5, Dvl, β-catenin, DKK1, and GSK-3β following to MH
exposure via RT-qPCR. The groups were normalized to elf-1α and analyzed using the 2-ΔΔCT
method. Data analysis was performed by non-parametric t-test followed by unpaired-t test. The
asterisk (*) represents value is significant compared to the control group (P<0.05). Each bar
represents mean ± SEM (N= 4 pools, 100 embryos/pool).
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3.10 Effect of MH on inflammatory mediators
This study was designed to assess the effect of MH on the expression of the major proinflammatory mediators. MH treatment (10 µM) upregulated the expression of IL-1β (2.5 fold),
TNF-α (1.9 fold) compared to the untreated group (Fig. 3.17).
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Figure 3.17: Gene expression of inflammatory mediators (IL-1β and TNF-α). The groups
were normalized to elf-1α and analyzed using the 2-ΔΔCT method. Data analysis was performed by
non-parametric t-test followed by unpaired-t test. The asterisk (*) represents value is significant
versus the control group (p<0.05). Each value represents mean ± SEM (n=4 pools, 100
embryos/pool).

55

3.11 Effect of MH on the cardiovascular system
MH (10 µM) appeared to have effect on the blood flow and heart for 0-6 dpf exposure (Fig 3.18).
Although the figures are in anterior and posterior position for control and treatment group,
respectively (Fig. 3.18), increased expression of the markers (cTnT, BNP A) for cardiovascular
abnormality (Fig. 3.15) showed the possibility of myocardial injury.
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Atrium
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Figure 3.18: Effect of MH on the cardiovascular system. Panel A and B represents the control
and MH (10 µM) treated group, respectively. The photographs were taken by Eclipse Ti2 inverted
microscope system (Nikon Instruments Inc., Melville, NY).
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3.12 Effect of MH on locomotion of medaka larvae:
The aim of this study was to assess the effect of MH on movement of medaka larvae.
Locomotion was evaluated in both dark and light conditions. The embryos were exposed to
different concentrations (0, 5 µM) of MH during the whole embryonic period (0-6 dpf) and
assessed for locomotion at 2 dph. The concentration was chosen to be 5 µM, because it was a
sub lethal concentration. The swimming behavior of Japanese medaka is phototactic in nature
which shows activation of swimming in light and inhibition in dark (Dasmahapatra et al., 2017).
Our control group shows similar pattern of locomotion activity in accordance with Dasmahapatra
et al. (2017). However, exposure of 5 µM MH exhibits an overall decreased duration of movement
(velocity ≥2 mm/sec), however the change was not significant with the control group (Fig. 3.20).
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Figure 3.19: Effect of MH on the locomotion (velocity ≥2mm/sec) of medaka larvae. Medaka
larvae (2 dph) were monitored for 40 min (0-10min dark, 10-20 min light, 20-30 min dark, 30-40
min light) using a ViewPoint Zebrabox. Duration of movements were measured at 2 min intervals
at a velocity of ≥2 mm/sec. Data were analyzed by two-way ANOVA followed by Bonferroni posthoc test. Each value represents mean ± SEM of 14-16 observations.
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CHAPTER 4: DISCUSSION

MH is a major bioactive constituent of Magnolia grandiflora seeds or Magnolia officinalis
bark. The Magnolia genus has been widely reported to have various beneficial effects on the
cardiovascular system, including anti-atherosclerosis, vascular relaxation, and antiplatelet effects
(Zhao et al., 2016). MH has been proven to be successful against high-fat diet-induced cardiac
pathogenic changes in mice (Zhang et al., 2015). However, the effect of this compound on the
cardiovascular system during embryogenesis has not been characterized yet.

This is the first study that shows the teratogenic potential of MH in a fish developmental
model. Previous studies showed toxic effects of different Magnolia genus on in vitro, in vivo, and
human subjects. Administration of 1 mg/ml Magnolia officinalis aqueous extract caused DNA
damage in human intestinal epithelial cells (FHs 74 Int) (Nachtergael et al., 2015). Another study
showed that 10 µM magnolol and honokiol were able to cause DNA damage in HK-2, a human
proximal tubule epithelial cells (Bunel et al., 2016). In the mice model, Magnolia bark extracts did
not show any toxicity and mortality; however, they showed slight fatty degeneration and sporadic
focal necrosis in the liver of 11 animals out of 40 with 240 mg/kg body weight administration (Liu
et al., 2007). Another study using dietary supplements containing extracts of M. officinalis and
Phellodendron amurense in human subjects demonstrated that 1 out of 22 persons reported side
effects including thyroid dysfunction, heartburn, perilabial numbness, shaking hands, sexual
dysfunction (Garrison and Chambliss, 2006). However, no explanations were provided whether
those effects were related to the treatments. A few mixtures containing Magnolia are also reported
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to be hepatotoxic by Teschke et al. (2014; 2015; 2016). However, no toxicological reports of MH
have been published so far.
Therefore, we have designed this experiment to determine the teratogenic potential of MH
on Japanese medaka and to elucidate the mechanisms that trigger this effect. Embryos were
treated with different concentrations of MH (0, 1, 2, 5, 10, 20 µM) throughout the whole embryonic
period (0-6 dpf) to observe whether MH induced any teratogenicity. Treatment with 10 µM MH
during the whole embryonic period showed 80% cumulative mortality at 10 dpf (Fig. 3.1).
Administration of 20 µM MH causes 100% cumulative mortality in the same period of time (Fig
3.1). The LC50 value for treatment during 0-6 dpf was 5.3 ± 0.1 µM (Fig. 3.1). The effect of MH on
hatching efficiency was also evaluated in our study, which showed significant decrease with 10
µM MH treatment (Fig 3.2), although we had not evaluated the mechanisms for this effect.
Previous studies reported that delayed development and fitness in the zebrafish embryos might
cause alterations in the hatching period due to decreased contractile movement (Alharty et al.,
2015; Danzmann et al., 1989; Pakkasmaa and Jones, 2002).

Another objective was to observe the effect of the compound on blood homeostasis. The
compound stopped blood circulation in 80% of embryos at 10 µM treatment compared to the
control group (Fig 3.3, 3.4). In medaka embryos, the heart first appears in stage 22, the tubular
heart forms in 23, and it becomes fully functional in stage 24 (1 day 20 hours) and starts beating.
Blood circulation starts in stage 25 (2 days 2 hours). Embryos start hatching from 7 dpf. The
heartbeat was counted at 3 dpf and 6 dpf. The heartbeat decreased significantly with 10 µM
exposure in 6 dpf compared to the 6 dpf control group (Table 3.1). Our study of MH exposure
throughout the whole embryonic period (0-6 dpf) suggested that it produced teratogenic potential
in Japanese medaka in a concentration-dependent manner.
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According to our observation, MH showed adverse effect on the cardiovascular system by
slowing down the heartbeat, impeding blood circulation, and inducing thrombus. Therefore, we
intended to see the effect of MH in case it is administered during the post circulation stage (2-6
dpf). Due to post circulation exposure with 10 µM MH, about 50% mortality was induced in 10 dpf
(Fig 3.5). Higher concentration of MH (20 µM) caused 100% abnormality in medaka embryos (Fig
3.5). The LC50 was higher in this case (9.9±0.2 µM) compared to the 0-6 dpf exposure (Fig 3.5).
The higher value of LC50 denotes less toxicity, which means it takes more of the compound to kill
half of the test chemicals. Therefore, LC50 value is a good indicator of toxicity of a compound.
However, treatment with 10 µM MH for 2-6 dpf also showed significant decrease in hatching
efficiency (Fig. 3.6). Moreover, the same concentration stopped blood circulation in a significant
number of embryos and induced blood vessel occlusion as a result (Fig. 3.7, 3.8). Furthermore
heart beat was decreased significantly in 6 dpf due to treatment with 10 µM MH for 2-6 dpf (Table
3.2). Our data indicated that MH demonstrated teratogenic potential on Japanese medaka in a
concentration-dependent manner regardless of the treatment period. Therefore, 10 µM MH
exposure throughout the whole embryonic period (0-6 dpf) or post circulation period (2-6 dpf)
produced teratogenicity in medaka embryos. Although MH has diverse therapeutic effects,
described previously, the potential teratogenic effects may limit its application during pregnancy.

We intended to identify the mechanism for MH induced thrombus formation at the
molecular level. Our goal was to observe if MH can induce gene expression of major components
of the extrinsic, intrinsic, and common blood coagulation pathways to produce the resultant
thrombus. Our data suggested that MH (10 µM) upregulated gene expression of FXI, FVII, and
FX (Fig. 3.9), which suggested that thrombus might be produced in medaka embryos due to
activation of major components of the blood coagulation pathway.

60

Moreover, we were interested to evaluate the effect of MH on the fibrinolytic system, which
acts as a regulatory mechanism in order to dissolve clots. Our data suggested that MH was able
to upregulate the expression of PAI-1 (Fig. 3.10) that might inhibit the conversion of plasminogen
into plasmin. PAI-1 prevents the actions of u-PA and t-PA from conversion of plasminogen to
plasmin (Dellas and Loskutoff, 2005). However, the expression of uPA was upregulated in our
study (Fig. 3.10). uPA is an important component of the inflammatory response, which mediates
leukocyte extravasation into the inflamed tissue and tPA regulates dissolution of fibrin in the
circulation (Bondu et al., 2018). Inflammatory mediators, such as TNF-α, IL-1β are involved with
upregulation of uPA (Kirchheimer and Remold, 1989). Therefore, MH mediated increased
expression of inflammatory mediators might upregulate the expression of uPA. The ratio of fold
differences between uPA and PAI-1 was calculated to be 1.2, and the ratio between tPA and PAI1 was 0.6 (Table 3.3), which suggest that MH might exhibit prothrombotic property.

We studied MH-mediated thrombus formation from another angles by looking at the
expression of the anti-oxidant enzymes and major receptors of the endothelial cells. First, we
evaluated the effect of the compound on the expression of major anti-oxidant enzymes. SOD acts
as a major defense system against superoxide in the vascular cells that catalyzes the dismutation
of superoxide anion to molecular oxygen and hydrogen peroxide (H2O2) (Wassmann et al., 2004).
SOD works as the first line of defense against ROS (Alscher et al., 2002). CAT is an intracellular
enzyme, which is effective against high levels of oxidative stress. It is located in the cellular
peroxisomes as well as in the cytosol. It catalyzes H2O2 to form water and molecular oxygen. It is
useful when the glutathione content is limited or when the GPX activity is decreased. The GPX or
GSH system is effective against low-level of oxidative stress. It is a selenium-containing
antioxidant enzyme that catalyzes the conversion of H2O2 into water and lipid peroxides into lipid
alcohols. H2O2 is elevated in the left ventricle after myocardial injury (Pendergrass et al., 2011). A
previous study showed that H2O2 upregulated the mRNA transcripts of the antioxidant enzymes
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such as CAT and GPX in the cardiac progenitor cells (CPC), which may protect the cells from
injury and also maintain the migratory ability of CPC to provide therapeutic regenerative benefits
in the damaged areas (Pendergrass et al., 2011). Another study showed that H2O2 addition
causes increase in mRNA levels of CAT, GPX, and SOD (Mates et al., 1999). Our data confirmed
that MH upregulated the mRNA transcripts of CAT, GPX 2 (Fig 3.11) suggested that it might be
due to increased oxidative stress by MH-induced myocardial injury. However, the compound did
not change the expression of SOD 2 (Fig 3.11). GST comprises up to 10% of cytosolic protein in
some mammalian organ (Boyer, 1989; Mukanganyama et al. 2011) and catalyzes the conjugation
of GSH into xenobiotic substrate for detoxification. GST A was reported in medaka fish genome
database and increased in postnatal life with the advancement of age (DeKoven et al., 1992; Wu
et al., 2011). GST is upregulated in response to oxidative stress (Nebert and Vasiliou, 2004). Our
study demonstrated that MH increased the expression of GST A gene (Fig. 3.11). This
upregulation of GST A might result from MH-induced oxidative stress. The stimulation of the major
anti-oxidant enzymes might be regulated through the induction of FoxO1 that is an important
regulator of the cellular stress response and promote the cellular antioxidant system (Klotz et al.,
2015). Our experiment showed that MH increased the gene expression of FoxO1, which might be
induced due to the increased oxidative stress produced by the compound (Fig. 3.12).
We also explored whether MH had any effect on the blood vessels to produce thrombus.
Endothelin (ET) consists of three isoforms, ET1, ET2, and ET3 (Yanagisawa et al., 1988; Inoue et
al., 1989). ETs interact with two heptahelical G-Protein coupled receptors, ET A and ETB (Arai et
al., 1990; Sakurai et al., 1990). All of the three isoforms interact with ET B with similar affinity
(Davenport, 2002; Davenport et al., 2006). Both of the receptors are present in the heart (Russell
and Molenaar, 2000); however, ETB predominates in the kidney (Maguire and Davenport, 2015).
In chronic heart failure (CHF) patients, increased levels of ET 1 were observed due to increased
production and decreased clearance of ET1 (Parker and Thiessen, 2004). In CHF, either ET A or

62

ETB receptors, and both receptors in other cases, were elevated (Sakai et al., 1996; Tonnessen
et al., 1998; Miyauchi et al., 1995; Kobayashi et al., 1999). Vascular endothelin production has
been reported to be high in atherosclerosis (Schneider et al., 2007). Increased ET B receptors
mediated vasoconstriction was observed in patients with atherosclerosis in a previous study
(Pernow et al., 2000). Increased expression of ETB receptors in the intima and media was also
observed in human atherosclerotic lesions (Iwasa et al., 1999). The increased expression of ET B
receptors may result in response to elevated production of ET 1 in order to clear the peptide
(Schneider et al., 2007). Our experiments exhibited that MH was able to increase the gene
expression of the ETB receptor (Fig. 3.13), which suggested that the compound might exert
vasoconstriction by ET1-mediated ETB receptor activation.
ATRAP gene product binds to the AT1 receptor (AT1R). ATRAP is a 18-kDa protein which
was first identified in 1999 (Daviet et al., 1999), it is co-localized with AT 1R in intracellular
compartments of mice and yeast, and triggers internalization and reduced signal of AT 1R (Daviet
et al., 1999; Lopez-Ilasaca et al., 2003). It is also expressed in migrating hypoblast, vasculature,
and in multiple embryonic epithelia in zebrafish model (Tucker et al., 2007). It is produced by
many organs, including the heart, kidneys, adrenal glands and testis. Angiotensin 2 acts through
ATRAP. It was noted in previous study that ATRAP knockout mice showed elevation in blood and
plasma volume through vasoconstriction and by increasing sodium and water retention in the
kidneys (Giani et al., 2013). Our data demonstrated that MH did not change the expression of the
ATRAP (Fig. 3.13), which indicated that the compound did not have any effect on the blood
vessels through AT1R.
We intended to characterize some markers associated with impaired cardiac structure
(NRG-2, ErbB3) and function (BNP A, Troponin T). First of all, the effect of MH was evaluated on
two major components of the NRG/ErbB pathway, including NRG-2 and ErbB3. Zebrafish has two
NRG genes, such as NRG-1, NRG-2 (Honjo et al., 2008). Both of the isoforms play important role
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in cardiac development (Rasouli and Stainier, 2017; Rupert and Coulombe, 2015). Both NRG-1
and 2 are identified in the embryonic endocardium, however only NRG-1 isoform continue to be
expressed in the adult heart (Carraway et al., 1997; Meyer et al., 1997; Cote et al., 2005; Zhao et
al., 1998; Yamada et al., 2000). Receptors for the cardiac specific NRGs are ErbB2, ErbB3, and
ErbB4 (Yarden and Sliwkowski, 2001). The NRG/ErbB interaction can activate several
downstream targets, including Erk1/2, PI3K/Akt, and JAK/STAT signaling cascades (Baliga et al.,
1999; Liu and Kern, 2002). Although, we did not investigate in details about the signaling
cascades, we analyzed the effect of MH on two major components (NRG-2, ErbB3) to explain
cardiac and developmental abnormalities. NRG-2 is required for cardiac trabeculation in zebrafish
(Rasouli and Stainier, 2017). Our data demonstrated MH downregulated the expression of NRG2 (Fig. 3.14), which might cause impairment in the cardiac structure. We also showed the effect
of MH on the expression of ErbB3 receptor, which is expressed in the mesenchymal cells of the
endocardial cushions of fetal heart and involved with the formation of the heart valves (Erickson
et al., 1997). ErbB3 knockout mice have been reported to induce defects in the endocardial
cushions and embryonic lethality (Odiete et al., 2012). Our data exhibited that MH decreased the
expression of the ErbB3 receptor (Fig. 3.14), suggesting the compound might disrupt cardiac
structure in medaka embryos.
We also aimed to assess the level of major markers (cTnT, BNP A) to confirm
cardiovascular abnormality mediated by MH. Our study demonstrated that MH upregulated the
gene expression of BNP A and cTnT that are good indicators for myocardial injury (Fig 3.15).
Yousif et al. (2017) mentioned that the increased levels of circulating cardiac troponin I (Tn-I) is
an indication of damaged heart muscle/ cardiovascular dysfunction in mice. Natriuretic peptide
genes have been identified as markers for cardiomyocyte hypertrophy and heart failure in
Zebrafish heart (Becker et al., 2012). BNP is a good example of the natriuretic peptide that has
been used as a marker for cardiovascular abnormality. BNP was first detected in porcine brain
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and consists of 32 amino acid. It is a polypeptide cardiac neurohormone secreted from the
membrane granules of the cardiac ventricle, mostly from the left ventricle, in response to
ventricular volume expansion and pressure overload (Dorothea et al., 2003). Elevated BNP is
associated with diverse cardiovascular abnormalities, including acute and chronic heart failure,
arrhythmias, cardiac ischemia, pulmonary disorder, and chronic renal diseases (Raizada et al.,
2007).
Troponin complex consists of Troponin C (cTnC- 18 KD), Troponin I (cTnI-26 KD) and
Troponin T (cTnT-39 KD), located on the thin filaments of striated muscle contractile apparatus
(Frey et al., 1998). Troponin T is a myofibril protein expressed only in myocardial cells. Although
2.8-4.1% cTnI and 6-8% cTnT are cytosolic, the troponins are predominantly bound to the
myofibrils (Wu and Feng, 1998). The presence of cTn in the serum is an indicator of myocardium
damage (Solnica, 2004). Troponin appears in blood 2-4 hours after insult, reaches the peak in
about 12 hours, and stays elevated for 7-10 days (Braunwald et al., 2001; Solnica, 2004;
Tarkowska and Furmaga-Jabłońska, 2012). It is widely used in diagnostic purposes for adults as
a marker for myocardial injury; however, its application in neonates has not been fully described
yet (Tarkowska and Furmaga-Jabłońska, 2012). An elevated serum level of troponin is indicative
of acute coronary syndrome and non-acute coronary syndrome, including chronic and acute heart
failure, arrhythmias, and myocarditis (Agzew, 2009). Tarkowska and Furmaga-Jabłońska (2012)
have stated the role of cTnT as a potential biomarker of congenital heart defects. Thus, increased
level of cTnT can be an indication of significant heart defects in newborns. Moreover, elevated
cTnT can be used as a marker for potential myocardial damage induced by persistent ductus
arteriosus (PDA) (El-Khuffash, 2008). Our study demonstrated that MH increased the expression
of cTnT significantly (Fig. 3.15), suggesting that the compound might cause myocardial injury.
The characterized markers showed the potential of impaired cardiac structure and function
in the MH treated medaka embryos. Therefore, we intended to shed some light on the Wnt/β65

catenin pathway to elucidate MH-mediated cardiovascular abnormality. Over activation of the
Wnt/β-catenin pathway at transcriptional level is involved with disruption in cardiac jogging and
looping affecting left-right asymmetry of the heart in zebrafish (Lin and Xu, 2009). Overexpression
of Wnt1 gene has been reported to be involved with cardiovascular injuries in medaka (Barjhoux
et al., 2016). The Wnt pathway is activated during development in response to developmental
cues in order to control cell differentiation and proliferation (Gomez-orte et al., 2013). The Wnt/βcatenin pathway is involved with the regulation of more than 50 mammalian genes (George,
2008). The potential of the canonical signaling of this pathway to upregulate the expression of
several genes in monocytes has raised the possibility that it may also be involved with
inflammation (Thiele et al., 2001). It is possible that expression of Wnts from macrophage and
dendritic cells has diverse impacts on the behavior of the resident cells (such as, endothelial cells
and vascular smooth muscle cells), including apoptosis (Lobov et al., 2005; Masckauchan et al.,
2006), migration (Cheng et al., 2007), proliferation (Masckauchan et al., 2006; Wang et., 2002;
Wang et al., 2004; Cheng et al., 2007), and invasion (Pukrop et al., 2006) through activation of
canonical and non-canonical signaling (George, 2008). Activation of the Wnt/β-catenin pathway
may be involved with upregulation of gene expression of inflammatory mediators, such as TNFα, IL-1β, IL-6 (Aumiller et al., 2013; Yousif et al., 2017). In several in vivo and in vitro studies,
these proinflammatory mediators have been induced in mRNA and protein levels (Aumiller et al.,
2013). Further studies are needed to confirm if the inflammatory mediators represent direct
targets of TCF/LEF-induced gene regulation (Aumiller et al., 2013). Previous studies showed that
IL-1β acted as a potent inducer of canonical (Ma et al., 2012) as well as noncanonical (Ryu et al.,
2006; Ge et al., 2009) Wnt ligands. This is why IL-1β is known as an upstream regulator of Wnt/βcatenin pathway in chondrocytes. Our study showed that MH was able to upregulate gene
expression of the ligand, Wnt1 of Wnt/β-catenin signaling pathway (Fig. 3.16). The compound
also increased the expression of the Fzd2 receptor and co-receptor LRP5 (Fig. 3.16). Thus MH
may increase the interaction between the Wnt ligand (Wnt1) with the Fzd receptor, leading to the
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formation of a cell surface complex with LRP5 by increasing their expression. This resultant
complex along with recruitment of the scaffolding protein Dvl causes phosphorylation of LRP5
and activation and recruitment of Axin complex to the receptors (Macdonald et al., 2009). Our
study also demonstrated that MH increased the expression of Dvl (Fig 3.16) that is an important
scaffold protein, acts between the Fzd receptor and the destruction complex (Wang et al., 2015).
Activation of the Wnt pathway triggers phosphorylation of Dvl and suppresses the downstream
destruction complex, although the mechanisms need further investigation (Clevers, 2006; Wang
et al., 2015). Dvl can also promote the β-catenin/TCF transcriptional complex formation, which is
pivotal for Wnt/ β-catenin complex (Barry et al., 2013; Gan et al., 2008; Habas and Dawid, 2005;
Torres and Nelson, 2000). Moreover, Wnt activation mediates nuclear translocation of Dvl that
acts along with its cytoplasmic functions to activate the Wnt/ β-catenin signaling pathway.
Increased expression of the major components of Wnt/β-catenin pathway by MH caused inhibition
of Axin-induced phosphorylation and stabilization of β-catenin (Fig. 3.16) that translocated to the
nucleus, and formed a complex with TCF/LEF and might activate Wnt responsive gene
expression, such as TNF-α, IL-1β.

A previous study showed that honokiol and magnolol exert anti-inflammatory effects by
blocking inflammatory cytokines/enzymes production, nuclear factor (NF-κB) activation, and
leukocyte activation (Fried and Arbiser, 2009). However, our data suggested that MH upregulated
gene expression of inflammatory cytokines, including TNF-α, IL-1β (Fig 3.17). This increased level
of inflammatory mediators might be expressed through the activation of the Wnt/β-catenin
signaling pathway. These inflammatory cytokines may further activate the Wnt/β-catenin pathway
by inducing Wnt 1, producing a self-perpetuating effect. Expression of inflammatory mediators
(TNF-α, IL-1β, IL-6) are increased following myocardial injury and sepsis (Al-Amran et al., 2011;
Wang et al., 2016). Previous studies have demonstrated the correlation between inflammatory
mediators and myocardial dysfunction (Yousif et al., 2011; Bravo et al., 2012; Yousif et al, 2017).
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Moreover, intravenous administration of TNF-α or IL-1β in animal models caused proinflammatory cytokine-mediated adverse effects leading to mortality, which was ameliorated by
antibodies via antagonizing their effects (Rispens et al., 2012; Yousif, 2014; Danielson et al.,
2016). Our study also indicated that MH-mediated excessive production of inflammatory
mediators might be involved with myocardial injury.

In previous findings, increased expression of DKK-1 of the Wnt/β-catenin pathway was
observed in clinical and experimental in vivo studies and in vitro studies on endothelial cells
(Ueland et al., 2009). In an ex vivo experiment, a high level of DKK-1 was produced in coronary
artery disease, reflecting increased release of DKK-1 in coagulation (Ueland et al., 2009). DKK-1
induced activation of the NF-kB inflammatory pathway in the platelet-activated endothelial cell
may contribute to the inflammatory interaction between platelet and endothelium (Ueland et al.,
2009). Expression of DKK-1 can be induced by inflammatory cytokines, such as TNF-α, which
occur within the atherosclerotic plaque (Diarra et al., 2007). DKK-1 derives from endothelium and
platelet cells, increase inflammatory interaction between those cells, showing a self-propagating
mechanism in the inflammatory microenvironment. Our study also demonstrated that MH
increased gene expression of DKK1 (Fig. 3.16). According to our data, the inflammatory response
might also be influenced by upregulation of DKK-1. The upregulation of DKK1 might result in order
to slow down the Wnt/β-catenin signaling pathway by interfering the binding of the Wnt1 ligand to
its receptor. However, further elucidations are needed to explain the overexpression of DKK1.
There are two isoforms of Glycogen synthase kinase 3 (GSK3) available in zebrafish,
GSK3-α and GSK3-β, which are encoded by different genes (Lee et al., 2007; Woodgett, 1990).
Both of the isoforms have role during zebrafish cardiogenesis (Lee et al., 2007). GSK3-α is
required for cardiomyocyte survival and GSK3-β is important for left-right asymmetry and
positioning of the heart (Lee et al., 2007). Deletion of the gene that encodes for GSK3-β is
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embryonically lethal, and GSK3-α is unable to rescue GSK3-β-null mice (Hoeflich, 2000). GSK3
is also an important regulator of the Wnt/β-catenin pathway. The β-catenin destruction complex
is composed of GSK3, axin, APC, and CK1α protein complex. GSK3 and CK1 are responsible for
phosphorylating axin and APC besides phosphorylating β-catenin, enhancing association of axin
and APC with β-catenin and increasing its phosphorylation and degradation (Huang and He,
2008; Kimelman and Xu, 2006). Inhibition of GSK3 activity leads to the stabilization and activation
of the β-catenin and TCF-dependent gene transcription (Klein and Melton, 1996; Stambolic et al.,
1996; Jope, 2003; Wu and Pan, 2009). Our data exhibited that GSK3-β expression was not
changed due to MH exposure during embryogenesis (Fig 3.16), which suggested that the
compound did not cause GSK-3β-mediated phosphorylation and degradation of β-catenin.
Control of cell cycle in cardiomyocytes is disrupted by diverse molecular events, including
gene overexpression or silence, gene amplification, or gene mutation, which can be regulated by
the Wnt/β-catenin pathway that plays a role in pathological changes in case of myocardial injury
and atherosclerotic plaque (Macdonald and He, 2012). Some of the inhibitors of this pathway
have been considered potential therapeutic targets of myocardial cell injury, and some are under
development (Kikuchi and Yamamoto, 2007). A recent study demonstrated that Wnt/β-catenin
expression was upregulated and stably expressed in myocardial injury (Yousif et al., 2017). Our
study also suggested that MH-induced myocardial injury might be caused by activation of the
Wnt/β-catenin pathway (Fig. 3.16) that was confirmed by the marker (Fig. 3.14, Fig 3.15) for
myocardial injury.

Yousif et al. (2017) has shown that inflammatory mediators, including TNF-α, IL-1β, IL-6,
were upregulated in cardiac tissue as well as in plasma of mice models for sepsis that was related
with worse left ventricle (LV) function through hemodynamic measurements (heart rate and
ejection fraction). Their results indicated that increased level of myocardial depressant
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proinflammatory mediators in the heart reduced cardiac contractility and induced myocardial injury
(Yousif et al., 2017). Our experiment also revealed that MH was able to decrease heart rate
significantly (Table 3.1) when administered with 10 µM concentration for 0-6 dpf. Therefore, MH
induced upregulation of pro-inflammatory mediators (Fig. 3.17) probably mediated through the
Wnt/β-catenin pathway (Fig. 3.16) might cause myocardial injury (Fig. 3.18) and embryonic
lethality that was characterized by decreased level of ErbB3, NRG-2 (Fig. 3.14), and increased
level of cTnT, BNP A (Fig 3.15), and decrease in heartbeat (Table 3.1).

Another objective of this project was to observe whether MH had any effect on the
locomotion phenotypes. As noted from our morphological data that MH prevented embryos from
hatching when they were treated with 10 µM concentration, so the embryos treated with sublethal
concentration of MH, 5 µM was used for the locomotion study. The swimming behavior of medaka
is considered as phototactic due to its activation of swimming during the light phase and inhibition
during the dark phase (Chiffre et al., 2016; Le Bihanic et al., 2015). In this study, we have
observed the effect of MH on locomotion of 2 dph larvae following a 0-6 dpf developmental
exposure with 5 µM concentration. Our data demonstrated that the medaka larvae did not show
any change in locomotion during the first dark cycle, probably due to the acclimatization of 20
minutes in a dark environment. The treatment group (5 µM) showed an overall decline in the
duration of swimming activity irrespective of the light-dark cycle after the first dark cycle, although
the change was not significant compared to the control group (Fig. 3.18).
In this project, the teratogenic concentration of MH was characterized in medaka embryos.
However, the human exposure dose needs to be determined. The following formula is used to
determine the human equivalent dose (HED): HED (mg/kg) = Animal dose (mg/kg) X (Animal Km/
Human Km) (Nair and Jacob, 2016; Shin et al., 2010). The Km is the correction factor, calculated
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by dividing the average body weight (kg) of species to its body surface area (m 2) (Nair and Jacob,
2016; Shin et al., 2010).

Figure 4.1: Schematic representation of the outcomes of MH (10 µM) on medaka embryos
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CHAPTER 5: CONCLUSION AND FUTURE PLAN

Magnolia constituents have been used in traditional Chinese and Japanese medicine for
years. MH, one of the major constituents of Magnolia, has gained lots of attention recently
because of its diverse therapeutic potential. Although the biological activities for MH are well
established, the toxicological studies have not yet been elucidated. So, the toxicities of MH and
their associated mechanism of actions should be illustrated before they get into the clinical trials
and approved as dietary supplements.
Our study was designed to evaluate the potential toxic effects of MH on medaka
embryogenesis to assess its risk during pregnancy. We concluded that MH could be deleterious
for the fetus in a concentration- and time-dependent manner. We characterized the mechanisms
for MH toxicity by analyzing different pathways at the molecular level. Moreover, we successfully
identified several markers, which can be used to evaluate cardiotoxicity in medaka.
However, there are some limitations of this study. The effect of MH on the medaka
embryos were evaluated until 10 dpf. The effect had not been characterized in the later stages
(30 dpf) due to some technical issues. Moreover, we could not measure the level of reactive
oxygen species due to lack of a standard positive and negative control in medaka embryos.
There was a significant difference in heart beat in the control groups between the 0-6 dpf
(Table 3.1) and 2-6 dpf exposure (Table 3.2) at 3 dpf and 6 dpf. These differences may be due to
variations in the experimental conditions or DMSO exposure throughout the whole embryonic
period for 0-6 dpf compared to the 2-6 dpf exposed embryos. Moreover, it was only visual
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observations. Therefore, further experiments are needed with cutting-edge microscopic
techniques to confirm the differences in heartbeat.
It is important to explore the effect of adverse events throughout life (Silveira et al., 2007).
This is a relatively new division of scientific knowledge, termed as the developmental origins of
health and disease (DOHaD). Future work should be performed to identify the adverse effects of
MH on adult fish. Moreover, the effect of the compound should be assessed on the next
generation to observe any potential cardiovascular abnormality.
Although we characterized the toxic potential of MH, we did not investigate the effect of
the parent compound, honokiol. Therefore, it will be interesting to observe the effect of honokiol
in medaka embryos.
To confirm the role of MH for inducing cardiovascular abnormality in medaka embryos
through Wnt/β-catenin pathway, Wnt 1 knockout from the embryo heart will be produced. Then
the embryos will be exposed to MH throughout the whole embryonic period and the effects will be
evaluated in morphological and molecular level.
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APPENDIX I Analytical characterization of MH uptake into medaka embryos by UHPLC/MS
analysis

A standard curve was prepared with different concentrations of MH between 1.8 µM and
35.7 µM. MH was collected in 1 dpf from the treatment media (10 µM) with embryo, which was
prepared from the same stock as the standard. Both were analyzed by UHPLC/MS analysis. The
method was described in chapter 2.
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Figure A1.1: Representative UHPLC chromatogram for MH (10 µM) standard. Wavelengths
of (A) 210 nm and (B) 254 nm were monitored for the DAD detector. MH was analyzed by ESI
and APCI in both positive and negative modes. APCI positive mode produced a better ion signal
for the tested compounds than other ionization modes. The MS was operated in (C) TIC as well
as (D) SIM mode. Retention time is 4.4
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Figure A1.2: Representative LC-MS spectra of MH (10 µM) standard from TIC at the
retention time 4.4 min. Quantitative ion, 281 m/z; Quantitative ion, 280.2 m/z; Quantitative
ion, 279 m/z
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Figure A1.3: Representative LC-MS spectra of MH (10 µM) standard from SIM at the
retention time 4.4 min. Quantitative ion, 281 m/z
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MH 10 µM- 1dpf
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Figure A1.4: Representative chromatogram generated by MH (10 µM) in 1 dpf. Wavelengths
of (A) 210 nm and (B) 254 nm were monitored for the DAD detector. MH was analyzed by ESI
and APCI in both positive and negative modes. APCI positive mode produced a better ion signal
for the tested compounds than other ionization modes. The MS was operated in (C) TIC as well
as (D) SIM mode. Retention time is 2.6
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Figure A1.5: Representative LC-MS spectra of MH (10 µM) at the retention time 2.6 min.
Quantitative ion, 393.2 m/z; Quantitative ion, 376.2 m/z
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The retention time for the 10 µM MH standard was 4.4 min (Fig. A1.1) which corresponded
m/z of 281.1 ([M+H]+) (Fig. A1.2, Fig. A1.3). Therefore, the molecular weight for the compound
was 280, which represented the presence of MH (C19H20O2). By analyzing the media of 1 dpf, we
observed that the HPLC peak corresponding for the standard solution disappeared and provided
a new peak at a retention time of 2.6 min (Fig. A1.4). The m/z for the new retention time was
393.2 ([M+H]+) (Fig. A1.5). Therefore, the molecular weight of the new compound was 392.
However, another peak represented the m/z to be 376.2 ([M+H]+) (Fig. A1.5) was observed, which
might be due to –OH group removal from the other compound that had the m/z of 393.2 ([M+H]+OH). The disappearance of the peak from the 1 dpf media (Fig. A1.4) might be due to uptake of
MH into the embryonic tissues. However, further studies are needed to confirm the uptake of the
compound by analyzing the embryonic tissues. Moreover, further illustrations are required for
identification of the compounds that were observed from 1 dpf media (Fig. A1.5).

114

APPENDIX II Representative agarose gel picture
The quality of the RT-qPCR product was evaluated by agarose gel electrophoresis (Fig.
A2.1) on a 2% agarose gel containing 0.01% ethidium bromide.
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Figure A2.1 Representative gel picture of RT-qPCR analysis of ErbB3, FoxO1, NRG-2, PAI1, tPA, uPA, Dvl, GST, GPX. The lanes are represented as (A) 100 bp ladder, (B) ErbB3-control,
(C) ErbB3-treatment, (D) FoxO1-control (E) FoxO1-treatment, (F) NRG-2- control, (G) NRG-2treatment, (H) PAI-1-control, (I) PAI-1-treatment, (J) tPA-control, (K) tPA-treatment, (L) uPAcontrol, (M) uPA-treatment, (N) Dvl-control, (O) Dvl-treatment, (P) GST-control, (Q) GSTtreatment, (R) GPX- control, (S) GPX-treatment
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